BEFORE THE

CITIZENS' FINANCIAL ACCOUNTABILITY OVERSIGHT COMMITTEE

ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: EMERYVILLE CITY COUNCIL CHAMBERS

1333 PARK AVENUE

EMERYVILLE, CALIFORNIA

DATE: THURSDAY, OCTOBER 1, 2015

9 A.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 97995

INDEX

ITEM DESCRIPTION	PAGE NO.
1. PLEDGE OF ALLEGIANCE	3
2. CALL TO ORDER AND ROLL CALL	3
3. OPENING STAATEMENT	4
4. ADOPT MINUTES OF THE FEBRUARY 20, 2013, AND JANUARY 22, 2014 CFAOC MEETINGS.	9
5 (A) PRESENTATION OF THE 2013-14 INDEPENDENT AUDIT BY MACIAS, GINI & O'CONNELL.	9
(B) STATE CONTROLLER'S OFFICE AUDIT REVIEW REPORT	13
6 (A) STATUS UPDATE OF CIRM'S FINANCIAL PERFORMANCE	15
(B) BUDGET	49
(C) PERFORMANCE AUDIT REPORT	68
7. DRAFT AGENDA	84
8. PUBLIC COMMENT	85
9. ADJOURNMENT	88

2

1	EMERYVILLE, CALIFORNIA; THURSDAY, OCTOBER 1, 2015
2	9 A.M.
3	
4	CHAIRWOMAN YEE: GOOD MORNING. WE ARE NOW
5	CONVENING AS THE CITIZENS FINANCIAL ACCOUNTABILITY
6	OVERSIGHT COMMITTEE. AND I ASK ALL OF YOU TO PLEASE
7	RISE FOR THE PLEDGE OF ALLEGIANCE.
8	(THE PLEDGE OF ALLEGIANCE.)
9	CHAIRWOMAN YEE: THANK YOU. GOOD MORNING.
10	AND THE REGULAR MEETING OF THE CITIZENS FINANCIAL
11	ACCOUNTABILITY OVERSIGHT COMMITTEE IS NOW CALLED TO
12	ORDER. LET ME INTRODUCE MR. ALAN LOFASO, MY DEPUTY
13	CONTROLLER FOR HEALTH POLICY, AND ASK HIM TO PLEASE
14	CALL THE ROLL.
15	MR. LOFASO: THANK YOU, CONTROLLER/MADAM
16	CHAIR. DR. MICHAEL QUICK.
17	MEMBER QUICK: PRESENT.
18	MR. LOFASO: DR. SEDANA GURBINDER. JIM
19	LOTT.
20	MEMBER LOTT: HERE.
21	MR. LOFASO: CONTROLLER BETTY YEE.
22	CHAIRWOMAN YEE: HERE.
23	MR. LOFASO: WE'RE ONE SHY OF A QUORUM.
24	CHAIRWOMAN YEE: OKAY. I KNOW THAT
25	DR. GURBINDER SEDANA WILL BE JOINING US IN THE LOS
	3

1	ANGELES OFFICE.
2	OUR PROCEEDINGS TODAY, JUST FOR THE PUBLIC
3	TO KNOW, IS BEING HELD FROM TWO LOCATIONS. WE'RE
4	HERE IN THE EMERYVILLE CITY COUNCIL CHAMBERS AS WELL
5	AS IN THE STATE CONTROLLER'S OFFICE IN LOS ANGELES.
6	AND WE HAVE DR. QUICK PRESENT WITH US. WELCOME.
7	WHAT I'D LIKE TO DO IS JUST START OUT WITH
8	SOME OPENING REMARKS AND WOULD EXTEND THAT ALSO TO
9	THE OTHER MEMBERS OF THE COMMITTEE. AND WE HAVE
10	SOME VERY GREAT PANELS COMING UP THAT WILL PROVIDE
11	US WITH SOME HIGHLIGHTS AND UPDATES, AND WE THEN
12	WILL LOOK AT TIME FOR PUBLIC COMMENT AS WELL.
13	SO LET ME JUST SAY WELCOME TO ALL OF YOU.
14	WE ARE MARKING OVER TEN YEARS SINCE CALIFORNIA
15	VOTERS EMBARKED ON A BOLD, INNOVATIVE \$3 BILLION
16	STATE-SPONSORED INITIATIVE TO FUND NEW ADVANCES IN
17	STEM CELL RESEARCH HERE IN CALIFORNIA. IN 2004 MANY
18	CALIFORNIANS WERE CONCERNED ABOUT RESTRICTIVE BUSH
19	ADMINISTRATION POLICIES LIMITING THE AVAILABILITY OF
20	EMBRYONIC STEM CELLS AND SHORT CHANGING THE
21	POTENTIAL TO ADVANCE LIFE-SUSTAINING TREATMENTS OR
22	STALLING OPPORTUNITIES TO SUBSTANTIALLY IMPROVE THE
23	QUALITY OF LIFE FOR PEOPLE WITH MAJOR PHYSICAL AND
24	NEUROLOGICAL BARRIERS.
25	AGAINST THAT BACKDROP, WE'VE SEEN SOME

1	MAJOR FOUNDATIONAL CHANGES IN STEM CELL RESEARCH
2	BEGINNING WITH THE ISOLATION OF EMBRYONIC STEM CELLS
3	JUST BEFORE THE BEGINNING OF THE CENTURY TO A MAJOR
4	BREAKTHROUGH OF REPROGRAMMING ADULT STEM CELLS.
5	EACH OF THESE HAS CHANGED MEDICAL RESEARCH IN
6	MULTIPLE WAYS. AND BY EXAMPLE, THE CALIFORNIA
7	INSTITUTE FOR REGENERATIVE MEDICINE OR WHAT WE WILL
8	REFER TO HERE TODAY AS CIRM, THEIR OWN WEBSITE LISTS
9	RESEARCH INITIATIVES FOCUSED ON 25 SEPARATE
10	MALADIES. EACH UTILIZES STEM CELLS IN A VARIETY OF
11	WAYS FROM GENERATING THE REMEDY TO KILLING THE
12	SOURCE OF THE PATHOGEN TO USING STEM CELLS IN THE
13	LAB FOR CLINICAL TESTING.
14	MOREOVER, CIRM'S RECENT LIST OF ADULT
15	CLINICAL TRIALS LISTS TREATMENTS DIRECTED TO AT
16	LEAST 11 SEPARATE ILLNESSES AND SOME HAVE ATTRACTED
17	BROAD MEDIA ATTENTION SUCH AS THIS YEAR'S
18	COLLABORATION WITH SANGAMO BIOSCIENCES RIGHT HERE IN
19	THE BAY AREA TO TEST A POTENTIAL CURE FOR HIV/AIDS
20	USING STEM CELLS TO GENERATE REPLACEMENT IMMUNE
21	CELLS. OTHERS ARE EQUALLY GROUNDBREAKING SUCH AS
22	THE ROLE OF ADVANCES IN REPROGRAMMED ADULT STEM
23	CELLS TO TREAT PARKINSON'S DISEASE
24	THE KEY QUESTION IS WHAT DRIVES THESE
25	ADVANCES. IS IT CALIFORNIA'S INVESTMENT? THE

5

1	FEDERAL GOVERNMENT'S INVESTMENT? PRIVATE INDUSTRY?
2	OTHER COUNTRIES? A COMBINATION OF MANY OR ALL OF
3	THESE? WHAT WE HOPE TO LEARN TODAY AND IN
4	SUBSEQUENT MEETINGS IS WHAT IS CIRM'S CONTRIBUTION
5	AND, MORE IMPORTANTLY, THE CALIFORNIA TAXPAYER'S
6	CONTRIBUTION TO THESE ADVANCES? BEYOND THE
7	REQUIREMENT THAT RESEARCH DOLLARS BE SPENT HERE IN
8	CALIFORNIA, WHAT MEASURABLE PROGRESS HAS THERE BEEN
9	TOWARDS CELEBRATING SUCCESSFUL CURES? AND HOW DO WE
10	EVALUATE CIRM'S ROLE IN ACHIEVING THOSE ADVANCES?
11	I KNOW WE WILL HEAR TODAY REGARDING MANY
12	RECENT CHANGES AT CIRM INCLUDING A CIRM 2.0
13	INITIATIVE AND ITS PLANS FOR THE NEXT FIVE YEARS. I
14	HOPE WE WILL ALSO BE FURTHER ABLE TO EVALUATE CIRM'S
15	WORK SINCE ITS INCEPTION, ITS CHALLENGES, ITS
16	SUCCESSES, AND WHAT TO BUILD ON FOR THE FUTURE. IS
17	PROPOSITION 71'S ACCOMPLISHMENT SIMPLY THE
18	ADDITIONAL RESEARCH FUNDS, ENHANCED COLLABORATION
19	AMONG RESEARCH INSTITUTIONS, ADDITIONAL LEVERAGE
20	FUNDS, COOPERATIVE PARTNERSHIPS WITH BIOTECH
21	COMPANIES, NEW RESEARCH TOOLS SUCH AS CIRM'S
22	RECENTLY ANNOUNCED STEM CELL BANK, AS A FORUM FOR
23	PATIENT ADVOCACY HERE IN CALIFORNIA? ULTIMATELY OUR
24	CHARGE TO HELP THE PUBLIC KNOW WHETHER IT HAS
25	RECEIVED ITS INVESTMENT AND WHERE CALIFORNIA'S
	_

6

1	EXPERIMENT IN STEM CELL RESEARCH IS HEADED IS THE
2	FOCUS OF THIS COMMITTEE.
3	FINALLY, TO CONTINUE PROPOSITION 71'S GOAL
4	OF ACCELERATING THE PROGRESS OF STEM CELL RESEARCH
5	FOR THE BENEFIT OF CALIFORNIANS, WE MUST KNOW WHAT
6	SHOULD THE FUTURE OF PUBLIC INVESTMENT IN STEM CELL
7	RESEARCH BE, WHAT FORM SHOULD IT TAKE, AND WHAT HAS
8	PROPOSITION 71 TAUGHT US? AND SO I THINK, AGAINST
9	THAT BACKDROP, AND I'M HAPPY TO BE JOINED HERE BY A
10	LONG-TIME COLLEAGUE, MR. LOTT, WHO I THINK HAS ASKED
11	THESE QUESTIONS CONSISTENTLY OVER YOUR TIME ON THIS
12	COMMITTEE, AND I'D LIKE TO TURN IT OVER TO YOU, MR.
13	LOTT FOR ANY OPENING COMMENTS YOU HAVE.
14	MEMBER LOTT: THANK YOU. AND GOOD
15	MORNING. A HEARTY WELCOME TO YOU, MADAM CONTROLLER.
16	AS YOU SAID, WE GO BACK A LONG WAY. I KNOW THE
17	EXPERIENCE, THE DEPTH OF UNDERSTANDING, AND YOUR
18	EXCELLENT ANALYTICAL SKILLS YOU WILL LEND TO US WILL
19	DO US WELL IN OUR ACHIEVING THESE POSSIBILITIES THAT
20	WE HAVE AS A COMMISSION.
21	AS YOU MENTIONED, I HAVE BEEN ON THE
22	COMMISSION SINCE ITS INCEPTION. CIRM IS AN
23	EXCELLENT ORGANIZATION, AND THE OVERSIGHT THIS
24	COMMITTEE, THIS COMMISSION, HAS BEEN PROVIDING HAS
25	ALSO BENEFIT REALLY WELL MANAGED UNDER THE FORMER
	7

1	CONTROLLER, YOUR PREDECESSOR, MR. CHIANG, AND I KNOW
2	YOU WILL CONTINUE TO BE THE STEWARD THAT HE WAS IN
3	GETTING US AGAIN TO MEET THE OBJECTIVES THAT WERE
4	SET FORTH IN PROPOSITION 71. SO I WANT TO WELCOME
5	YOU AND THANK YOU.
6	CHAIRWOMAN YEE: THANK YOU. THANK YOU,
7	MR. LOTT. DR. QUICK FROM LOS ANGELES, WOULD YOU
8	LIKE TO PROVIDE ANY OPENING COMMENTS?
9	MEMBER QUICK: YES. THANK YOU, CONTROLLER
10	YEE. THANK YOU SO MUCH FOR YOUR LEADERSHIP IN THIS.
11	I AM HONORED TO BE ON THE COMMITTEE. I JUST WAS
12	SWORN IN BY ALAN TWO MINUTES AGO, AND SO HONORED TO
13	BE SERVING ON THIS COMMITTEE. I SHARE EVERYONE'S
14	VIEW THAT NOT ONLY IS THIS AN IMPORTANT STEP FOR
15	SCIENCE, AND WE HAVE A GREAT RESPONSIBILITY TO MAKE
16	SURE THAT WE ARE MAKING IT CLEAR TO THE PUBLIC WHAT
17	WE ARE DOING AND HOW WE'RE BEING GOOD STEWARDS OF
18	THE PEOPLE'S MONEY. I PLAN ON TAKING THAT VERY
19	SERIOUSLY, AND I'M JUST PLEASED TO BE A PART OF THE
20	COMMITTEE AND A PROGRAM THAT IS REALLY, ONCE AGAIN,
21	SHOWING HOW CALIFORNIA CAN LEAD THE WORLD. AND SO
22	I'M VERY MUCH LOOKING FORWARD TO WORKING WITH ALL OF
23	YOU. THANK YOU.
24	CHAIRWOMAN YEE: THANK YOU, DR. QUICK, AND
25	WELCOME. I LOOK FORWARD TO OUR SERVICE TOGETHER.

1	LET ME MOVE ON NOW TO AGENDA ITEM NO. 4,
2	WHICH IS ADOPTION OF THE MINUTES OF THE FEBRUARY
3	20TH, 2013, AND JANUARY 22, 2014, COMMITTEE
4	MEETINGS. I KNOW THIS IS A BIT UNUSUAL. WE HAVE
5	MEMBERS WHO ARE HERE TODAY WHO WERE NOT SERVING ON
6	THE COMMITTEE DURING THOSE MEETINGS, BUT I HAVE BEEN
7	ADVISED THAT, FOR THE RECORD, IT IS ADVISABLE THAT
8	WE PROCEED TO ADOPT THE MINUTES. AND I KNOW WE'RE
9	LACKING A QUORUM AT THIS POINT. SHOULD WE HOLD OFF
10	ON THAT?
11	MR. LOFASO: WE SHOULD WAIT.
12	CHAIRWOMAN YEE: WE'LL WAIT TILL DR.
13	SEDANA JOINS US THEN.
14	VERY WELL. WHY DON'T WE PROCEED, THEN, TO
15	ITEM NO. 5, WHICH IS THE PRESENTATION OF THE
16	INDEPENDENT FINANCIAL AUDIT BY MACIAS, GINI &
17	O'CONNELL. AND WE WILL CONVENE THIS PANEL FOR
18	THOSE LET'S SEE, DR. QUICK, I BELIEVE, YOU HAVE
19	THE MATERIALS IN FRONT OF YOU FOR THIS PRESENTATION.
20	WE'LL BE LOOKING AT TABS 3 AND 4. OKAY. AND FOR
21	THIS PANEL WE HAVE PRESENTING CRAIG HARNER WITH
22	MACIAS, GINI & O'CONNELL AND LARRY KNAPP FROM THE
23	STATE CONTROLLER DIVISION OF AUDITS. GOOD MORNING.
24	MR. HARNER: MORNING. MY NAME IS CRAIG
25	HARNER, AUDIT MANAGER AT MACIAS, GINI & O'CONNELL.
	q
	7

1	BEFORE I BEGIN MY PRESENTATION, I JUST WANT TO THANK
2	THE COMMITTEE FOR GIVING US THE TIME TO PRESENT THE
3	RESULTS OF OUR WORK.
4	SO WE WERE ENGAGED TO AUDIT THE FINANCIAL
5	STATEMENTS OF THE GOVERNMENTAL ACTIVITIES AND THE
6	MAJOR FUNDER OF THE STEM CELL FUND OF CIRM FOR THE
7	FISCAL YEAR ENDED JUNE 30, 2014, AND THE RELATED
8	NOTES TO THE FINANCIAL STATEMENTS WAS COMPRISED FOR
9	CIRM'S BASIC FINANCIAL STATEMENTS.
10	BEFORE I GET TO THE RESULTS OF OUR AUDIT,
11	I JUST WANT TO GO OVER A COUPLE OF THE
12	RESPONSIBILITIES THAT MANAGEMENT HAS OVER THE
13	FINANCIAL STATEMENTS AS WELL AS THE INDEPENDENT
14	AUDITORS. MANAGEMENT IS RESPONSIBLE FOR THE
15	PREPARATION AND THE FAIR PRESENTATION OF THE
16	FINANCIAL STATEMENTS IN ACCORDANCE WITH ACCOUNTING
17	PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES
18	OF AMERICA, AND THIS ALSO INCLUDES THE DESIGN,
19	IMPLEMENTATION, AND MAINTENANCE OF INTERNAL CONTROL
20	AS RELEVANT TO THE PREPARATION OF AND PRESERVATION
21	OF THOSE FINANCIAL STATEMENTS TO ENSURE THAT THOSE
22	ARE FREE OF WHAT'S CALLED MATERIAL MISSTATEMENT
23	WHETHER DUE TO ERROR OR FRAUD.
24	NOW, AS AN AUDITOR OUR RESPONSIBILITY IS
25	TO EXPRESS AN OPINION ON THOSE FINANCIAL STATEMENTS

1	BASED ON OUR AUDIT. SO WE CONDUCTED OUR AUDIT IN
2	ACCORDANCE WITH AUDITING STANDARDS GENERALLY
3	ACCEPTED IN THE UNITED STATES AND THEN ALSO THE
4	STANDARDS APPLICABLE TO FINANCIAL AUDITS CONTAINED
5	IN THE GOVERNMENT AND THE GOVERNMENT AUDITING
6	STANDARDS. AND THESE STANDARDS ARE FOLLOWED TO
7	PERFORM THE AUDIT TO OBTAIN WHAT'S CALLED REASONABLE
8	ASSURANCE ABOUT WHETHER THE FINANCIAL STATEMENTS ARE
9	FREE OF MATERIAL MISSTATEMENT. A REASONABLE
10	ASSURANCE IS A HIGH LEVEL OF ASSURANCE, BUT IT'S NOT
11	100 PERCENT OF ASSURANCE. WE DON'T LOOK AT EVERY
12	SINGLE TRANSACTION; HOWEVER, WE GET A VERY HIGH
13	LEVEL IN ORDER FOR US TO MAKE SURE THAT WE'RE
14	REASONABLY FREE OF MATERIAL MISSTATEMENT.
15	AND SO YOU WILL SEE FOR THE AUDIT FOR THE
16	PERIOD ENDING JUNE 30, 2014, WE ISSUED AN AUDIT
17	REPORT OCTOBER 13, 2014, AND WE ISSUE WHAT'S CALLED
18	AN UNMODIFIED OPINION. AN UNMODIFIED OPINION IS THE
19	HIGHEST LEVEL OF ASSURANCE THAT AN AUDITOR CAN GIVE
20	AN ORGANIZATION REGARDING THEIR FINANCIAL
21	STATEMENTS.
22	AND WITH THAT, ARE THERE ANY QUESTIONS ON
23	OUR AUDIT?
24	CHAIRWOMAN YEE: QUESTIONS, MR. LOTT?
25	MEMBER LOTT: NEGATIVE.
	11

11

_	
1	CHAIRWOMAN YEE: OKAY. NO QUESTIONS. LET
2	ME JUST ASK YOU AS A NEW MEMBER OF THIS BODY PERHAPS
3	COULD YOU JUST REMIND US WHERE CIRM'S FINANCIAL
4	DISCLOSURE DOCUMENTS ARE FILED?
5	MR. HARNER: WHERE THEY'RE FILED?
6	CHAIRWOMAN YEE: YEAH. WHERE THEY ARE
7	KEPT AND WHERE ARE THEY FILED?
8	MR. HARNER: I'M NOT SURE I'M FOLLOWING
9	THAT.
10	CHAIRWOMAN YEE: SO ONCE THE STATEMENTS
11	ARE DEVELOPED AND YOU FINISH YOUR AUDIT, ARE THEY
12	PROVIDED TO ANYONE?
13	MR. HARNER: OH, YES. THEY'RE PROVIDED TO
14	THE STATE CONTROLLER'S OFFICE.
15	CHAIRWOMAN YEE: ANY OTHER OUTSIDE
16	PARTIES?
17	MR. HARNER: OFF THE TOP OF MY HEAD, I
18	DON'T BELIEVE SO. YOU KNOW THEY MIGHT BE PART OF
19	THE CONTINUING DISCLOSURE OF FINANCE; BUT OFF THE
20	TOP OF MY HEAD, I DON'T KNOW THAT. I KNOW THEY ARE
21	PROVIDED TO THE STATE CONTROLLER'S OFFICE, AND STATE
22	CONTROLLER'S OFFICE REVIEWS OUR WORK.
23	CHAIRWOMAN YEE: I'M AWARE OF THAT. OKAY.
24	THANK YOU.
25	WHY DON'T WE THEN HEAR FROM THE STATE
	12

1	CONTROLLER'S OFFICE.
2	MR. KNAPP: GOOD MORNING. I'M LARRY
3	KNAPP. I'M WITH THE STATE CONTROLLER'S OFFICE, AND
4	I'M WITH THE FINANCIAL AUDITS BUREAU. I'M HERE TO
5	PRESENT THE RESULTS OF THE STATE CONTROLLER'S OFFICE
6	QUALITY CONTROL REVIEW OF MACIAS, GINI & O'CONNELL'S
7	AUDIT OF CIRM FOR THE FISCAL YEAR 2013-14.
8	THE CALIFORNIA HEALTH AND SAFETY CODE ACT
9	SECTION 125290.30 REQUIRES THE SCO TO CONDUCT A
10	QUALITY CONTROL REVIEW OF CIRM'S ANNUAL FINANCIAL
11	AUDITS AND TO ISSUE A PUBLIC REPORT OF THAT REVIEW.
12	AS PART OF OUR REVIEW, WE COMPARED THE AUDIT WORK
13	PERFORMED BY THE FIRM AS DOCUMENTED IN YOUR
14	WORKPAPERS WITH APPLICABLE AUDITING STANDARDS AND
15	REQUIREMENTS WHICH INCLUDE GOVERNMENT AUDITING
16	STANDARDS, GENERALLY ACCEPTED AUDITING STANDARDS,
17	AND ALSO THE CALIFORNIA BUSINESS AND PROFESSIONS
18	CODE AND THE RELATED CALIFORNIA BOARD OF ACCOUNTANCY
19	REGULATIONS.
20	BASED ON OUR REVIEW, WE DETERMINED THAT
21	THE MACIAS, GINI & O'CONNELL AUDIT OF CIRM FOR THE
22	FISCAL YEAR 2013-14 WAS PERFORMED IN ACCORDANCE WITH
23	ALL APPLICABLE STANDARDS OR REQUIREMENTS FOR
24	FINANCIAL AUDITS. WE NOTE NO DEFICIENCIES IN THEIR
25	AUDIT WORK.

1	DOES ANYONE HAVE ANY OUESTTONS?
1	DOES ANYONE HAVE ANY QUESTIONS?
2	CHAIRWOMAN YEE: OKAY. ANY QUESTIONS OR
3	COMMENTS FROM MEMBERS? OKAY. THANK YOU, MR. KNAPP.
4	MR. KNAPP: THANK YOU.
5	CHAIRWOMAN YEE: LET ME JUST DO A QUICK
6	CHECK. IN OUR LOS ANGELES LOCATION, DO WE DID
7	ANOTHER COMMITTEE MEMBER JOIN US?
8	MEMBER QUICK: YES. DR. SEDANA JUST
9	JOINED US.
10	CHAIRWOMAN YEE: THANK YOU. GOOD MORNING,
11	DR. SEDANA. WELCOME.
12	DR. SADANA: THANK YOU.
13	CHAIRWOMAN YEE: OKAY. WITH THE PRESENCE
14	OF DR. SEDANA, WE NOW HAVE A QUORUM OF THE
15	COMMITTEE. LET ME GO BACK, IF I COULD, TO ITEM NO.
16	4, THE ADOPTION OF THE MINUTES OF THE FEBRUARY 20,
17	2013, AND JANUARY 22, 2014, COMMITTEE MEETINGS.
18	MEMBER LOTT: MADAM CHAIR, SINCE
19	DR. SEDANA AND I, I THINK, WERE THE ONLY TWO MEMBERS
20	AT THAT POINT, IT IS MY PLEASURE TO MOVE ADOPTION OF
21	THE MINUTES.
22	CHAIRWOMAN YEE: THANK YOU VERY MUCH. WE
23	HAVE A MOTION BY MR. LOTT. DR. SEDANA, A SECOND
24	FROM YOU?
25	DR. SADANA: YES. I SECOND.
	14

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	CHAIRWOMAN YEE: THANK YOU. MOTION AND A
2	SECOND. WITHOUT OBJECTION, MEMBERS? THE COMMITTEE
3	MEETING MINUTES OF BOTH MEETINGS ARE APPROVED.
4	THANK YOU.
5	DR. SEDANA, WELCOME.
6	DR. SADANA: HI.
7	CHAIRWOMAN YEE: WE GAVE EACH OF THE
8	COMMITTEE MEMBERS AN OPPORTUNITY FOR SOME OPENING
9	STATEMENTS. AND THANK YOU FOR YOUR CONTINUING
10	SUSTAINED SERVICE TO THIS COMMITTEE. DO YOU WISH TO
11	OFFER ANY OPENING COMMENTS?
12	DR. SADANA: NOTHING AT THIS POINT, BUT
13	THANK YOU.
14	CHAIRWOMAN YEE: THANK YOU. AND WE WILL
15	MOVE ON, THEN, TO ITEM NO. 6, WHICH IS THE STATUS
16	UPDATE OF CIRM'S FINANCIAL PERFORMANCE, CURRENT
17	BUDGET, AN UPDATE OF GRANTS AWARDED, AND THE GRANT
18	PROCESS. AND FOR THIS, MEMBERS, WE WOULD DIRECT
19	YOUR ATTENTION TO TABS 5 AND 6. AND ON THIS ITEM WE
20	HAVE DR. JONATHAN THOMAS, THE ICOC CHAIRMAN; CHILA
21	SILVA-MARTIN, FINANCE DIRECTOR; AND MARIA
22	BONNEVILLE, THE EXECUTIVE DIRECTOR AND DIRECTOR OF
23	ADMINISTRATION. GOOD MORNING.
24	CHAIRMAN THOMAS: GOOD MORNING, MADAM
25	CONTROLLER AND MEMBERS OF THE CFAOC. IT IS OUR
	1.5

1	PLEASURE TO BE HERE TO PRESENT YOU WITH AN UPDATE ON
2	THE MANY EXCITING DEVELOPMENTS THAT ARE TAKING PLACE
3	AT CIRM SINCE WE LAST APPEARED BEFORE THIS BODY.
4	FOR THOSE ON THE PHONE, I WOULD JUST LIKE TO LET YOU
5	KNOW THAT HERE JOINING ME TODAY FROM CIRM ARE
6	SENATOR ART TORRES, THE VICE CHAIR OF OUR BOARD; WE
7	HAVE JAMES HARRISON, GENERAL COUNSEL TO CIRM; AND
8	MARIA BONNEVILLE, WHO IS OUR EXECUTIVE DIRECTOR TO
9	THE BOARD AND HEAD OF ADMINISTRATION; WE HAVE DR.
10	GIL SAMBRANO, WHO IS THE DIRECTOR OF GRANTS REVIEW.
11	WE HAVE DOUG GUILLEN, EXECUTIVE ASSISTANT TO SENATOR
12	TORRES. AM I LEAVING ANYBODY OUT HERE? I THINK
13	THAT'S OH, AND, YES, OF COURSE, AND CHILA
14	SILVA-MARTIN, WHO IS OUR DIRECTOR OF FINANCE WHO
15	WILL FOLLOW ME IN THIS PRESENTATION.
16	DR. QUICK, WELCOME TO THE CFAOC. IT'S A
17	PLEASURE TO MEET YOU. PLEASE SAY HELLO TO DEAN
18	PULIAFITO, WHO, AS YOU KNOW, IS A LONGTIME AUGUST
19	MEMBER OF OUR GOVERNING BOARD.
20	MEMBER QUICK: I WILL SURELY DO SO.
21	CHAIRMAN THOMAS: THANK YOU. WE HAVE A
22	SLIDE PRESENTATION WHICH IS TO ACCOMPANY MY
23	COMMENTS, AND I'M WONDERING DO MEMBERS
24	CHAIRWOMAN YEE: WE'LL TAKE A MOMENT. WE
25	NEED TO HAVE ACCESS ONLINE TOO.

16

1	(PAUSE IN PROCEEDINGS.)
2	CHAIRWOMAN YEE: OKAY. I BELIEVE WE ARE
3	BACK ONLINE. LET ME PROCEED.
4	DR. THOMAS.
5	CHAIRMAN THOMAS: OKAY. THANK YOU VERY
6	MUCH, MADAM CONTROLLER. I THOUGHT THAT I'D GIVE TWO
7	SECONDS OF BACKGROUND WHILE WE'RE ON THIS FIRST
8	SLIDE HERE JUST FOR THE NEW MEMBERS OF THE
9	COMMITTEE. I HAVE NOW BEEN, HARD TO BELIEVE,
10	CHAIRMAN ALREADY OF CIRM FOR THE PAST FOUR AND A
11	HALF YEARS. MY BACKGROUND IS ORIGINALLY AS A
12	BIOLOGIST, ALSO MANY YEARS IN LAW, PUBLIC FINANCE,
13	AND GOVERNMENT, WHICH IS SOMETHING THE COMBINATION
14	OF WHICH HAVE BEEN HELPFUL IN HELPING WITH OUR
15	COLLEAGUES HERE TO OVERSEE ALL THE VARIOUS ACTIONS
16	OF THE AGENCY.
17	WHY I AM HERE, AS WE ALL ARE, AS YOU KNOW,
18	14 MILLION CALIFORNIANS SUFFER FROM ONE SORT OF
19	CHRONIC DISEASE OR INJURY OR ANOTHER. LIKE
20	EVERYBODY IN THIS ROOM, I STAND TO BENEFIT,
21	HOPEFULLY, BY THE THINGS THAT CIRM IS DOING AND THE
22	MANY ADVANCES THAT WE FIELD HERE IN THE PROCESS OF
23	FACILITATING THROUGH OUR WORK.
24	I LOOK FORWARD TO SPEAKING TO YOU TODAY TO
25	GIVE YOU AN UPDATE ON WHERE THINGS ARE GOING, WHERE
	17

1	WE ARE. WE'VE, SINCE WE WERE LAST BEFORE YOU, BEEN
2	JOINED BY A NEW PRESIDENT, DR. RANDY MILLS, FORMERLY
3	THE CEO OF A STEM CELL COMPANY IN BALTIMORE CALLED
4	OSIRIS THERAPEUTICS. DR. MILLS JOINED US IN MAY OF
5	2014. HE'S SOMEBODY THAT WE BROUGHT ON BECAUSE WE
6	FELT AT THIS STAGE IN CIRM'S LIFE IT WAS TIME TO GET
7	SOMEBODY WHO WAS WELL VERSED IN THE ACTUAL CLINICAL
8	TRIAL PART OF THE RESEARCH SPECTRUM AND WHO BROUGHT
9	EXPERTISE IN STEM CELLS AND DEALING WITH REGULATORY
10	AGENCIES AND ISSUES IN DEALING WITH THE MANY
11	CHALLENGES OF THE CLINICAL TRIAL PROCESS, WHICH IS
12	NO TRIVIAL THING, SOMEBODY WHO WAS AN ARDENT PATIENT
13	ADVOCATE, AND SOMEONE WHO COINCIDENTALLY WAS
14	FAMILIAR WITH CIRM AND WHAT WE DO.
15	AS IT TURNS OUT, THOUGH HE WAS THE CHOICE
16	AFTER LITERALLY AN INTERNATIONAL SEARCH, HE ACTUALLY
17	HAD CONSIDERABLE FAMILIARITY WITH CIRM AS A
18	FIVE-YEAR MEMBER OF OUR PEER REVIEW GROUP WHICH WE
19	CALL THE GRANTS WORKING GROUP. SO IN SUM, HE WAS
20	ABLE TO COME IN, KNEW WHAT WE WERE ABOUT, KNEW WHAT
21	WE HAD BEEN DOING, HAD ACTUALLY PARTICIPATED IN WHAT
22	WE HAVE BEEN DOING, AND WAS ABLE TO HIT THE GROUND
23	RUNNING.
24	THIS MORNING I WANT TO GIVE YOU A
25	PRESENTATION, A BIT OF OUR HISTORY, GIVE YOU AN

1	UPDATE ON OUR CURRENT FUNDED PROGRAMS, WANT TO TELL
2	YOU, AS MADAM CONTROLLER HAS MENTIONED, VERY
3	EXCITING NEW DEVELOPMENTS IN OUR PROCESSES WHICH WE
4	CALL CIRM 2.0, AND THEN TO WALK YOU THROUGH A BIT OF
5	
	WHERE WE PLAN TO BE GOING FROM THIS POINT FORWARD,
6	WHICH IS TO GIVE SOME HIGHLIGHTS OF OUR PROPOSED
7	STRATEGIC PLAN.
8	MOVING OVER TO SLIDE 2, RIGHT HERE, OKAY.
9	SO JUST TO GIVE YOU A BIT OF BACKGROUND ON CIRM, IN
10	2004 THE AGENCY WAS CREATED. FIFTY-NINE PERCENT OF
11	THE CALIFORNIA VOTERS APPROVED OF IT, AND IT WAS
12	SOMETHING THAT WAS DESIGNED, MADAM CONTROLLER, TO
13	TRY TO DRAMATICALLY JUMP START, ACCELERATE THE THEN
14	FLEDGLING FIELD OF STEM CELL BIOLOGY ON THE THOUGHT
15	THAT STEM CELLS COULD WELL BE THE SOURCE OF GREAT
16	ADVANCEMENT IN THE QUEST TO DEFEAT THE MANY
17	UNTREATABLE DISEASES AND CONDITIONS THAT ARE OUT
18	THERE AT THIS POINT.
19	WE AT CIRM FELT THAT THIS GAVE THE AGENCY
20	A NOT ONLY SENSE OF PURPOSE, BUT DRAMATIC SENSE OF
21	URGENCY. WE ARE IN THE PROCESS OF ACTIVELY
22	PARTNERING IN THIS QUEST WITH ACADEMICS IN THE
23	STATE, WITH INDUSTRY IN THE STATE, WITH BOTH
24	ACADEMIA AND INDUSTRY NATIONALLY AND INTERNATIONALLY
25	THROUGH VARIOUS COLLABORATIVE FUNDING AGREEMENTS

1	THAT WE HAVE. AND WHAT WE'VE CREATED HERE IS A \$3
2	BILLION ENDEAVOR. WE CURRENTLY HAVE OVER 300 ACTIVE
3	PROGRAMS. WE ARE, WITHOUT A DOUBT, THE LARGEST
4	FUNDER OF STEM CELL RESEARCH IN THE WORLD. AND AS
5	SUCH, HAVE PLAYED A DRAMATIC ROLE IN ACCELERATING
6	THE PACE OF DISCOVERY IN THE FIELD BOTH IN
7	CALIFORNIA, NATIONALLY, AND INTERNATIONALLY.
8	IN EVERY MEETING WE HAVE NOW, DR. MILLS
9	HAS INSISTED, WHICH I THINK IS GREAT, THAT WE NEVER
10	LOSE SIGHT OF OUR MISSION, WHICH, SIMPLY STATED, IS
11	ACCELERATING STEM CELL TREATMENTS TO PATIENTS WITH
12	UNMET MEDICAL NEEDS. EVERYTHING WE DO IS WITH THAT
13	IN MIND.
14	SO A BIT ON WHERE WE ARE AT THIS POINT.
15	WE'VE HAD, AS YOU CAN SEE FROM THIS SLIDE, 668
16	AWARDS SINCE INCEPTION, TOTALLING \$2 BILLION. THOSE
17	BREAK DOWN INTO FIVE CATEGORIES. THE TOP TWO ARE
18	EDUCATIONAL PROGRAMS, WHICH I'LL SAY A BIT MORE
19	ABOUT, AND INFRASTRUCTURE, WHICH WAS THE DEVELOPMENT
20	OF FACILITIES IN WHICH TO DO STEM CELL RESEARCH UP
21	AND DOWN THE STATE. AND THEN THE BOTTOM THREE, AS
22	YOU CAN SEE THERE, WHICH WE CALL DISCOVERY,
23	TRANSLATIONAL, AND CLINICAL, YOU SHOULD THINK OF AS
24	THE THREE PARTS OF THE RESEARCH CONTINUUM STARTING
25	WITH BASIC RESEARCH ALL THE WAY UP THROUGH PHASE III

20

1	CLINICAL TRIALS, WHICH WE WILL TALK ABOUT IN A BIT.
2	WITH RESPECT TO INFRASTRUCTURE, AS YOU CAN
3	SEE, THESE ARE A COUPLE OF OUR FACILITIES, ONE AT
4	STANFORD, ONE AT IRVINE. AT THE TIME THAT THE
5	AGENCY WAS FORMED, YOU MIGHT RECALL THAT BECAUSE
6	PRESIDENT BUSH HAD PUT A STOP BASICALLY ON FUNDING
7	OF NEW EMBRYONIC STEM CELL RESEARCH WITH FEDERAL
8	DOLLARS, YOU HAD TO BE ABLE TO DISCRETELY AND
9	SEPARATELY SHOW THAT WORK THAT WAS BEING DONE IN
10	THIS CASE WITH CALIFORNIA DOLLARS WAS NOT MIXED UP
11	WITH ANY FEDERAL FUNDING. SO THERE WERE A LOT OF
12	NEW FACILITIES BUILT. SO UNAMBIGUOUSLY YOU COULD
13	TELL THAT WE WERE CONDUCTING RESEARCH UP AND DOWN
14	THE STATE FUNDED SOLELY BY CIRM DOLLARS, NOT TO BE
15	MIXED UP WITH FEDERAL DOLLARS. AND WE HAVE 12
16	FACILITIES STATEWIDE.
17	SOME ARE NEW STANDALONE BUILDINGS, SOME
18	WERE REFURBISHMENTS OF EXISTING FACILITIES. CIRM
19	PUT 271 MILLION IN. WE LEVERAGED THAT, AND THIS IS,
20	I THINK, VERY NOTEWORTHY, AGAINST 844 MILLION OF
21	PRIVATE PHILANTHROPIC OR FOUNDATION DOLLARS, WHICH
22	SHOWED THE LEVEL OF INTEREST AND ENTHUSIASM IN THE
23	PRIVATE SECTOR WITH THE FIELD OF STEM CELL RESEARCH.
24	WE HAVE A STUDY THAT WE HAD COMMISSIONED
25	AT UC BERKELEY WHICH SHOWED THAT IN 2014 WE HAD OVER
	21

1	200 MILLION IN TAX REVENUE GENERATED BY CIRM-FUNDED
2	PROGRAMS AND 25,000 JOB YEARS OF WORK DONE AS A
3	RESULT.
4	ON THE EDUCATIONAL FRONT, ONE OF THE FIVE
5	PILLARS YOU SAW HERE, OBVIOUSLY ONE OF THE MAJOR
6	REASONS FOR US TO EXIST, AND ONCE THE MAJOR
7	CHALLENGE WAS OVER, WE PUT IN PLACE AN EDUCATIONAL
8	PROGRAM THAT WOULD TRAIN WHAT WE FELT NEEDED TO BE
9	THE FUTURE OF THE WORKFORCE THAT WOULD POPULATE STEM
10	CELL PROGRAMS THAT WE ARE FUNDING. TOWARDS THAT
11	END, WE'VE HAD A NUMBER OF VERY SUCCESSFUL PROGRAMS.
12	FIRST ON YOUR SCREEN, THE RESEARCH
13	LEADERSHIP AWARDS. THIS WAS A SET OF AWARDS WHERE
14	WE WOULD HELP INSTITUTIONS THAT WERE LOOKING TO
15	BASICALLY LURE AWAY TOP CLASS SCIENTISTS FROM
16	DIFFERENT INSTITUTIONS OUTSIDE THE STATE OF
17	CALIFORNIA TO COME WORK AND LEAD THE STEM CELL
18	PROGRAMS IN THEIR RESPECTIVE INSTITUTIONS.
19	SECONDLY, WE HAVE NEW FACULTY AWARDS,
20	WHICH ARE AWARDS THAT ARE FUNDING M.D. AND PH.D.
21	SCIENTISTS IN CRITICAL EARLY STAGES OF THEIR
22	CAREERS. I WILL NOTE FOR THE RECORD THAT, WHILE WE
23	HAVE THESE TWO PROGRAMS, THERE WERE, AND THIS IS A
24	KEY POINT, MANY SCIENTISTS WHO CAME TO CALIFORNIA
25	WHO WHEN THEY CAME DID NOT ACTUALLY HAVE FUNDING
	22

1	FROM CIRM, BUT THEY CAME BECAUSE THEY KNEW CIRM HAD
2	FUNDING AND CAME IN THE HOPES OF GETTING DOLLARS FOR
3	THEIR RESEARCH EFFORTS. AND I THINK AT LAST COUNT
4	WE'RE OVER 200 WORLD-CLASS SCIENTISTS HAVE MOVED TO
5	CALIFORNIA AND BROUGHT WITH THEM THEIR POST DOCS AND
6	EVERY MULTIPLIER ASPECT OF THE WORK THAT THEY HAVE
7	IN THEIR RESEARCH LABS AND HAVE ADDED GREATLY TO THE
8	ALREADY EXTREMELY IMPRESSIVE TALENT OF RESEARCHERS
9	IN THE STATE.
10	THE LAST THREE ITEMS UP HERE, I THINK, ARE
11	VERY IMPORTANT. THE TRAINING AWARDS, WHICH WE GAVE
12	TO GRADUATE AND POSTGRADUATE STUDENTS, THE BRIDGES
13	AWARDS, WHICH ARE A PRODUCT OF SENATOR TORRES, WHO
14	IS VERY PROUD OF THIS, WHICH IS MONEY THAT WE GIVE
15	TO UNDERGRAD AND GRADUATE STUDENTS AT PLACES THAT DO
16	NOT HAVE STEM CELL PROGRAMS THAT ALLOWS THEM TO GO
17	TO PLACES THAT DO IN THE STATE AND BECOME PART OF
18	THEIR PROGRAM FUNDED BY US. AND THIS HAS BEEN A
19	TREMENDOUSLY SUCCESSFUL PROGRAM. IF YOU WERE TO GO,
20	AS WE DO ON AN ANNUAL BASIS, AND LISTEN TO THE
21	BRIDGES STUDENTS WHO CONVENE ONCE A YEAR TO TALK
22	ABOUT WHAT THEY'RE DOING, THEY ARE NOT ONLY
23	UNENDINGLY ENTHUSIASTIC, BUT THEY ARE EXTREMELY
24	IMPRESSIVE IN WHAT THEY HAVE BEEN ABLE TO DO IN THE
25	FIELD. AND IF YOU TALK TO THE INSTITUTIONS WHERE

1	THEY ACTUALLY ARE WORKING AND STUDYING, YOU WILL
2	HEAR THAT TIME AFTER TIME THESE BRIDGES STUDENTS
3	HAVE CONTRIBUTED SIGNIFICANT PARTS OF THE RESEARCH
4	THAT IS GOING INTO PROJECTS THAT WE FUND AND ARE AN
5	INTEGRAL PART OF THAT. IT'S BEEN A VERY SUCCESSFUL
6	PROGRAM.
7	THE LAST, CREATIVITY AWARDS, WHICH WE
8	RENAMED THE SPARK AWARDS, WHICH IS AN ACRONYM, THIS
9	IS ONE OF MY FAVORITE PERSONAL THINGS. THESE ARE
10	HIGH SCHOOL KIDS WHO ARE GOING TO SUMMER PROGRAMS
11	THAT CIRM FUNDS TO LEARN ABOUT STEM CELL RESEARCH.
12	AND WHEN THEY START ON DAY ONE, THEY KNOW NOTHING OF
13	THE FIELD, THEY KNOW NOTHING OF THE VERNACULAR; AND
14	BY THE END OF THE SUMMER, THEY DO A DAY WHERE WE ALL
15	CONVENE AND THEY PRESENT POSTERS ON THEIR WORK. AND
16	YOU WOULD THINK YOU WERE TALKING TO PH.D. STUDENTS.
17	THESE KIDS ARE LITERALLY UNBELIEVABLE IN WHAT
18	THEY'RE ABLE TO PICK UP, WHICH IS NOT ONLY A TRIBUTE
19	TO THEM AND THEIR INTELLECTUAL CURIOSITY, BUT TO THE
20	PROFESSORS AND DOCTORS THAT RUN THESE PROGRAMS AT
21	THE INSTITUTIONS THAT WE FUND FOR THAT PURPOSE.
22	GOING DOWN THIS FULL LIST, THIS DOES
23	REPRESENT, WE BELIEVE, A MAJOR PART OF THE
24	WORKFORCE, AS I SAY, THAT WILL BE COMING DOWN THE
25	LINE HERE TO WORK ON THE MANY EXCITING PROJECTS THAT
	24
	· • · · · · · · · · · · · · · · · · · ·

1	WE HAVE GOING AND OTHER PROJECTS THAT ARE GOING THAT
2	WE HAVEN'T FUNDED AS WELL.
3	SO A QUICK REVIEW HERE. WE'VE GOT A PIE
4	CHART UP THERE. WE HAVE HAD A BILLION THREE
5	INVESTED IN VERY SPECIFIC DISEASES. I THINK THERE
6	WAS, MADAM CONTROLLER, I THINK OUR WEBSITE MUST BE
7	IN ERROR. YOU NOTED THAT WE HAVE FUNDED MORE THAN
8	25 DIFFERENT DISEASES. I BELIEVE THAT NUMBER IS,
9	GIL, OVER 40 NOW. YES. SO THAT NUMBER IS ACTUALLY
10	OVER 40 WHICH TAKES INTO ACCOUNT NOT ONLY ALL OF THE
11	MAJOR DISEASES, SUCH AS CANCER, DIABETES,
12	NEUROLOGICAL DISORDERS, VISION DISORDERS, WHATEVER,
13	BUT ALSO INCLUDES A NUMBER OF RARE OR SO-CALLED
14	ORPHAN DISEASES. YOU CAN SEE THE GENERAL CATEGORIES
15	OF WHAT WE'RE FUNDING REPRESENTED HERE ON THE PIE
16	CHART, SO I WON'T GO THROUGH THAT. BUT AS YOU CAN
17	SEE, IT COVERS A LOT OF DIFFERENT AREAS. AND, IN
18	FACT, I THINK WE COVER MOST EVERY AREA THAT ONE CAN
19	THINK OF.
20	SO THIS IS AN INTERESTING PAGE. SO, MR.
21	LOTT, WHEN WE WERE HERE LAST TIME, YOU ASKED US
22	ABOUT WHAT OUR PROGRESS WAS. AT THAT POINT IN
23	JANUARY OF 2014, WE HAD TWO CLINICAL TRIALS, AS I
24	RECALL, IN PROCESS. THE NOTE THAT EVEN THOUGH CIRM
25	WAS PASSED IN 2004, IT WASN'T UNTIL 2007 WE ACTUALLY
	25

1	STARTED FUNDING ANYTHING BECAUSE WE HAD LITIGATION
2	DURING THAT PERIOD. AND REMEMBER, WE STARTED FROM
3	ABSOLUTE SCRATCH. AND THE FIELD WAS ESSENTIALLY
4	STARTING FROM SCRATCH. SINCE THAT TIME, WE NOW HAVE
5	15 DIFFERENT PROGRAMS THAT ARE IN HUMAN CLINICAL
6	TRIALS, WHICH WE THINK IS QUITE A LIST. THAT
7	INCLUDES A NUMBER OF PHASE I, PHASE II, AND PHASE
8	III CLINICAL TRIALS. YOU SEE ON YOUR SCREEN THERE
9	THE GENERAL DISEASES TO WHICH THOSE TRIALS APPLY.
10	AND WE HAVE IN YOUR MATERIALS, WHICH I WOULD WELCOME
11	YOU TO READ, WHICH ARE MERCIFULLY IN PLAIN ENGLISH,
12	A BIT OF TWO- OR THREE-SENTENCE RECITATION ON EACH
13	OF THESE 15 CLINICAL TRIALS THAT I INVITE YOU TO
14	READ AT YOUR LEISURE, BUT I THINK THAT WE AT CIRM
15	ARE VERY PLEASED WITH THE PROGRESS OF THE PIPELINE.
16	WE HAVE, MEMBERS OF THE COMMITTEE, A NUMBER OF
17	PROJECTS THAT ARE GOING TO BE FOLLOWING, WE EXPECT,
18	BY THE END OF THIS YEAR TO HAVE AS MANY AS, I LOOK
19	AT GIL, 20. BY THE END OF CALENDAR 2015, AS MANY AS
20	20 PROJECTS IN HUMAN CLINICAL TRIALS WITH MANY MORE
21	BACKED UP BEHIND THAT.
22	NEXT SLIDE HERE, THIS IS SORT OF A RECAP
23	OF OUR FUNDING. WE HAVE
24	MEMBER LOTT: EXCUSE ME. I JUST WANT TO
25	PAUSE AND SAY THANK YOU. THIS IS VERY, VERY ON
	2.0

26

1	POINT. I LOVE THE FACT THAT IT'S IN SIMPLE ENGLISH.
2	THIS IS TERRIFIC. THIS IS WHAT WE'VE BEEN WANTING.
3	I REALLY APPRECIATE YOUR EFFORTS AT THIS.
4	CHAIRMAN THOMAS: THANK YOU VERY MUCH. I
5	THINK WE'RE VERY PROUD OF THIS. AND I THINK THE
6	CITIZENS OF CALIFORNIA SHOULD BE VERY PROUD OF THIS
7	AND EVERYTHING THAT'S GOING TO COME FROM THIS. AND
8	IT IS SCIENCE, SO ULTIMATELY THINGS WILL PLAY OUT AS
9	THEY PLAY OUT, BUT WE HAVE, I THINK, DONE AND ARE IN
10	PROCESS OF DOING WHAT WE WERE CHARGED TO DO, WHICH
11	IS TO PUT TOGETHER A ROBUST RESEARCH PROGRAM
12	STATEWIDE THAT WAS SOMETHING THAT THE VOTERS WANTED
13	AND DESERVE. SO I APPRECIATE VERY MUCH YOUR
14	COMMENT.
15	ON THE SLIDE ENTITLED "FUNDING RUNWAY," WE
16	HAVE SO FAR AWARDED TWO BILLION. AND WE SAY
17	AWARDED. THAT'S BOTH ACTUALLY SPENT OR ALLOCATED.
18	OUR PROGRAMS TAKE SEVERAL YEARS TYPICALLY, SO THAT
19	MONEY WILL BE SPENT OVER A SEVERAL YEAR PERIOD OF
20	TIME. WE HAVE 775 MILLION UNCOMMITTED AT THIS
21	POINT. 190 TO 200 MILLION IN NEW AWARDS PER YEAR.
22	AS YOU KNOW, PROJECTS THAT ARE FUNDED DON'T ALWAYS
23	WORK OUT. SO EACH YEAR WE'RE GOING TO HAVE PROJECTS
24	THAT IS MUTUALLY DECIDED NEED TO BE BROUGHT TO A
25	CLOSE, AND THAT WILL PUT SOME MONEY BACK INTO THE
	27

1	CIRM BUCKET. AND THAT'S, WE ESTIMATE, 20 MILLION A
2	YEAR IN THAT CATEGORY. SO ON A NET BASIS WE BELIEVE
3	WE'LL BE SPENDING ABOUT 170 MILLION A YEAR GIVE OR
4	TAKE GOING FORWARD, WHICH WILL, GIVEN THE AMOUNT
5	THAT WE HAVE NOW, TAKE US THROUGH THE YEAR 2020. SO
6	WE HAVE ABOUT ANOTHER FIVE YEARS TO GO ON THAT
7	FUNDING.
8	OKAY. SO IN REFERENCE TO CIRM 2.0, WHAT
9	IS THAT? SO DR. MILLS CAME IN AND HE WAS CHARGED
10	WITH TAKING STOCK OF WHAT WE HAD IN PLACE. HE
11	DETERMINED THAT WE HAD A GREAT PROGRAM, BUT, LIKE
12	ALL PROGRAMS, ANYTHING CAN STAND TO BE IMPROVED.
13	AND SO HE DID AN OVERHAUL OF THE WAY WE DO BUSINESS
14	WITH AN EYE TOWARDS A FASTER, MORE EFFICIENT PROCESS
15	THAT WOULD ACTUALLY GET FUNDING OUT TO PROJECTS
16	SOONER AND WOULD, AS A RESULT, GET ULTIMATELY WHAT
17	WE HOPE ARE THERAPIES TO PATIENTS SOONER. AND AS
18	YOU CAN SEE THERE, THE EMPHASIS WAS ON SPEED,
19	PARTNERSHIPS, AND PATIENTS, AND WE'LL TALK ABOUT
20	EACH.
21	OKAY. SO THE PURPOSE OF CIRM 2.0 IS THERE
22	ARE MANY, MANY HIGH QUALITY PROJECTS AND PROCESSES
23	IN THE STATE OF CALIFORNIA. WE WANTED TO GENERATE A
24	GREATER NUMBER OF THOSE COMING TO CIRM IN A REDUCED
25	PERIOD OF TIME TO GET THROUGH THE EVALUATION AND

1	FUNDING PROCESS WHICH WOULD RESULT IN A FASTER
2	PROGRESSION OF PROJECTS AND ALL WITH AN EYE TOWARDS
3	TRANSPARENCY AND CLARITY SO THAT EVERYBODY HAS A
4	FULL SENSE OF WHAT IT IS THAT WE ARE DOING.
5	FEATURES OF CIRM 2.0, WE HAVE, AGAIN,
6	WHICH I'LL TALK ABOUT A DRAMATIC EXAMPLE, A FASTER
7	PROCESS TO GET THROUGH THE GRANT REVIEW. WE HAVE
8	WHAT WE BELIEVE IS AN EVEN WE HAVE PARTNERSHIPS
9	WITH OUR PROJECTS OF THE PRINCIPAL INVESTIGATOR AND
10	THEIR TEAMS THAT WE'VE FUNDED OVER THE YEARS, BUT WE
11	NOW HAVE WHAT WE THINK IS AN EVEN MORE HANDS-ON
12	PROCESS OF PARTNERSHIP WITH THEM, WHICH IS A BIG
13	DEAL BECAUSE, FOR THOSE OF YOU FAMILIAR WITH NIH
14	FUNDING, NIH WILL AWARD GRANTS WHICH ARE THE
15	LIFELINE OF ANY RESEARCHER, AND THEY'LL SAY HERE IS
16	YOUR FUNDING AND GOOD LUCK. WE HOPE THAT THIS WORKS
17	OUT AS YOU HAVE PRESENTED TO US. WE BELIEVE THAT
18	THERE IS MORE THAN THAT THAT WE CAN DO TO HELP.
19	SO WITH EACH OF OUR MAJOR PROJECTS, WE
20	HAVE SOMETHING CALLED A CLINICAL ADVISORY PANEL THAT
21	WE PUT TOGETHER, WHICH IS A PANEL OF EXPERTS AND AT
22	LEAST, AND THIS IS VERY IMPORTANT, ONE PATIENT WHO
23	HAS THE DISEASE OR AFFLICTION AT ISSUE. AND THIS
24	PANEL WORKS WITH THE INVESTIGATORS OVER THE COURSE
25	OF THEIR RESEARCH TO HELP THEM IMPROVE AS THEY GO
	20

1	ALONG AND FINE-TUNE WHAT IT IS THEY'RE DOING ALL
2	WITH AN EYE TOWARDS GETTING A MORE SUCCESSFUL RESULT
3	AT THE END.
4	THE FUNDING IS OPEN TO THE FULL ARRAY OF
5	DIFFERENT TYPES OF THERAPEUTIC CANDIDATES, WHETHER
6	IT'S CELLS THEMSELVES OR SO-CALLED BIOLOGICS OR
7	SMALL MOLECULES, WHICH, FOR THOSE OF YOU WHO AREN'T
8	FAMILIAR WITH DRUG DEVELOPMENT LINGO, JUST MEANS
9	DRUGS. THEY CALL THEM SMALL MOLECULES. WE HAVE,
10	AND THIS IS IMPORTANT TOO, ALL OF OUR MONEY NEEDS TO
11	BE SPENT WITHIN CALIFORNIA, BUT WE ARE INTERESTED IN
12	GETTING PIECES OF THE BEST IN CLASS PROJECTS FROM
13	LITERALLY ALL OVER THE WORLD TO BE IN CALIFORNIA SO
14	THAT WE CAN PARTICIPATE. SO WE ARE ACTIVELY
15	ENCOURAGING BEST IN CLASS PRINCIPAL INVESTIGATORS TO
16	APPLY FOR CIRM FUNDING IF THEY CAN ESTABLISH A NEXUS
17	FOR SOME PART OF THAT PROJECT. SO, FOR EXAMPLE, IF
18	SOMEBODY AT HARVARD, FOR EXAMPLE, HAS A PROJECT AND
19	THEY WANT TO CONDUCT SOME OF THEIR CLINICAL TRIALS
20	FOR THAT PROJECT IN CALIFORNIA, WE ARE ACTIVELY
21	ENCOURAGING THEM TO APPLY FOR FUNDING FOR THAT
22	CLINICAL TRIAL COMPONENT. WE CAN'T FUND WHAT
23	THEY'RE DOING IN BOSTON, BUT WE CAN FUND WHATEVER IS
24	DONE HERE. SO WE ARE REALLY TRYING TO EVEN FURTHER
25	INCREASE THE POOL OF PROJECTS THAT WE HAVE HERE IN
	20

1	THE STATE SO AS TO EVEN MORE RESPONSIBLY DEPLOY
2	TAXPAYER DOLLARS FOR THE GREATEST GOOD AT THE END OF
3	THE DAY.
4	WE HAVE AS A CRITICAL COMPONENT OF THIS A
5	WHAT WE CALL READY-WHEN-YOU-ARE PROTOCOL SET UP
6	WHERE INSTEAD OF, AS WAS THE CASE PREVIOUSLY,
7	WAITING A NUMBER OF MONTHS FOR THE PERIODIC
8	ISSUANCES OF REQUESTS FOR GRANT APPLICATION FOR YOU
9	TO APPLY. WITH OUR LARGEST PROJECTS NOW, WE HAVE
10	SET UP LITERALLY A MONTHLY APPLICATION ROLLING
11	PROCESS WHERE WHEN YOU'RE READY TO APPLY, YOU DON'T
12	HAVE TO WAIT FOR 12 TO 24 MONTHS FOR THE NEXT RFA.
13	YOU CAN LITERALLY FLY. OUR PEER REVIEW, WHICH
14	PREVIOUSLY HAD MET PERIODICALLY, NOW MEETS MONTHLY.
15	IF THEY COME UP WITH SOMETHING THEY RECOMMEND FOR
16	FUNDING, OUR BOARD NOW MEETS MONTHLY. MOST OF THOSE
17	MEETINGS ARE TELEPHONIC. AND THEY CONSIDER THE
18	APPLICATIONS THAT WERE PROPOSED FOR FUNDING IN THE
19	PEER REVIEW THE PREVIOUS MONTH. SO WHAT IT ALLOWS
20	FOR IS A REAL SPEED-UP OF THE PROCESS. STILL OUR
21	GRANTS ARE EXTREMELY COMPETITIVE. I DON'T KNOW HOW
22	MANY OF YOU EVER SAT IN ON A GRANT REVIEW ITSELF,
23	BUT THEY ARE MARKED BY INCREDIBLE DILIGENCE AND
24	EFFORT AND EXPERTISE THAT THESE PEER REVIEWERS BRING
25	TO PLAY TO RECOMMEND PROJECTS TO US THAT ARE ONLY
	21

1	THE BEST IN CLASS.
2	OKAY. SO I SHOULD NOTE ON THAT LAST POINT
3	THAT OUR BIGGEST PROJECTS NORMALLY TOOK UP TO 24
4	MONTHS TO GO FROM REQUEST FOR APPLICATION TO ACTUAL
5	FUNDING. WE'VE NOW GOT THAT DOWN TO A LITTLE OVER
6	FOUR MONTHS. SO, AS YOU CAN SEE, WE'VE STREAMLINED
7	THAT PROCESS DRAMATICALLY WITHOUT IN ANY WAY
8	AFFECTING THE HIGH QUALITY OF THE WORK THAT WE ARE
9	FUNDING.
10	SO WE NOW GO ON TO SORT OF WHERE ARE WE
11	GOING FORWARD. THE SLIDE UP THERE ON THE STRATEGIC
12	PLAN AND THE PROCESS AND THAT THERE ARE, WE FIGURE,
13	THREE THINGS TO LOOK AT: WHERE ARE WE NOW? WHERE
14	DO WE WANT TO GO? AND HOW DO WE GET THERE? AND
15	EACH OF THOSE HAS A NUMBER OF COMPONENTS.
16	I SHOULD TELL YOU, BY THE WAY, THE
17	STRATEGIC PLANNING PROCESS IS IN PLACE REAL-TIME.
18	WE WENT TO OUR LAST BOARD WITH A FRAMEWORK FOR THAT
19	PROCESS WHICH IS GOING TO BE REVIEWED BY THE SCIENCE
20	SUBCOMMITTEE AND OUR BOARD ITSELF AGAIN AS A FINAL
21	PRODUCT IN OUR DECEMBER BOARD MEETING AND WOULD
22	INVITE ANY OF YOU WHO ARE INTERESTED TO LISTEN IN TO
23	THAT. I THINK IT WILL BE A MOST INTERESTING
24	DISCUSSION.
25	SO A FEW HIGHLIGHTS FROM THE PLAN HERE.

1	I'M NOT GOING TO GO INTO TOO MUCH DETAIL ON THE
2	SLIDE. THIS IS SORT OF DR. MILLS' VERNACULAR UP
3	HERE, WHICH IS THE PUSH, PULL, LEVEL CONCEPT. SO
4	WHERE ARE WE RIGHT NOW? WE ARE PUSHING ALONG OUR
5	PROJECTS. WE HAVE NOW PUT IN PLACE CIRM 2.0 NOT
6	JUST FOR THE LARGER PROJECTS, BUT FOR ALL OF THE
7	PROJECTS IN THE EARLIER PART OF THE SPECTRUM, WHICH
8	WE CALL DISCOVERY AND TRANSLATION. SO NOW EVERY
9	TYPE OF FUNDING AWARD HAS BEEN 2.0-IZED, IF YOU
10	WILL. THE PROCESS IS ONE WHERE WE'RE ACTIVELY
11	PUSHING THINGS AND CONSTANTLY MOVING THINGS ALONG
12	THE SPECTRUM. WE WANT TO ENCOURAGE PARTIES TO BE ON
13	THE OTHER END PULLING THEM TOWARDS THEM, INTERESTED
14	PARTIES THAT WE CAN BRING INTO THE FOLD THAT WILL
15	HELP MOVE THINGS ALONG.
16	ONE OF THE THINGS THAT WE'VE NOTED IS
17	WE'VE LOTS OF EARLY STAGE RESEARCH, AND EARLY
18	RESEARCHERS AREN'T NECESSARILY THE ONES WHO WOULD
19	TAKE THAT RESEARCH INTO THE LATER STAGES IN CLINICAL
20	TRIALS. AND THERE'S BEEN A BIT OF A DISCONNECT IN
21	HOW TO MATCH UP THE EARLY STAGE RESEARCHERS WITH THE
22	LATER STAGE RESEARCHERS. SO WE ARE LOOKING TO PUT
23	IN PLACE SOMETHING CALLED THE CIRM EXCHANGE, WHICH
24	DR. MILLS LIKES TO REFER AS OUR MATCH.COM WHICH AIMS
25	TO BE ABLE TO DEVELOP A CONTINUUM WHERE ONE

1	RESEARCHER IN AN EARLY STAGE PROJECT LITERALLY CAN
2	PASS THAT ALONG, IF IT'S APPROVED FOR FUNDING, TO A
3	LATER STAGE RESEARCHER SUCH THAT YOU HAVE A SEAMLESS
4	CONTINUUM OF WORK BEING DONE DRIVING ULTIMATELY
5	TOWARDS THE CLINICAL TRIAL PROCESS AND HOPEFULLY
6	DEVELOPMENT OF A THERAPY THAT CAN GO TO PATIENTS.
7	WE ALSO ARE CONTEMPLATING A NUMBER OF
8	PUBLIC/PRIVATE PARTNERSHIPS WITH RESPECT TO OUR
9	PROGRAMS. THIS IS THE WHOLE ISSUE OF TRYING TO JOIN
10	TOGETHER INDUSTRY THAT IS LOOKING FOR EARLY STAGE
11	AND R&D AND PIPELINE. AND WITH OUR RESEARCHERS WHO
12	WANT TO BE ABLE TO ACCESS FUNDING AND THE LIGHT AT
13	THE END OF THE TUNNEL, THAT WILL HELP THEM TAKE
14	THEIR PROJECTS THROUGH TO COMMERCIALIZATION. THAT'S
15	ON THE PULL SIDE.
16	SO THE LEVEL SIDE TAKES NOTE OF THE FACT
17	THAT BECAUSE STEM CELLS ARE STILL A YOUNG FIELD, THE
18	REGULATORY HURDLES HAVE BEEN SIGNIFICANT. THE FDA,
19	AS IT TENDS TO DO WITH NEW FIELDS, HAS A VERY
20	CONSERVATIVE, DELIBERATIVE PROCESS. AND LIKE ANY
21	NEW FIELD, IT IS ONE THAT, THROUGH EDUCATION,
22	DEVELOPS OVER TIME IN A WAY THAT IS MORE AND MORE
23	CONDUCIVE TO HELPING THE RESEARCH MOVE ITS WAY
24	ALONG. WE BELIEVE THAT THERE ARE REAL OPPORTUNITIES
25	HERE TO HELP EDUCATE THE REGULATORS AND TO BASICALLY
	2.4

1	MAKE IT SO THAT REGULATORY HURDLE IS NOT AS HIGH AS
2	IT IS CURRENTLY, AND ULTIMATELY WE WILL BE ABLE TO
3	HELP THEM. AND THIS IS NOT GOING TO BE EASY, BY THE
4	WAY. IT'S GOING TO REQUIRE A WHOLE HOST OF
5	STAKEHOLDERS TO COME TOGETHER TO HELP IN THAT
6	PROCESS, BUT ULTIMATELY WILL LEAD TO A BETTER
7	PROCESS AND A MORE STREAMLINED PROCESS.
8	WE NOTE, FOR EXAMPLE, THAT JAPAN, WHICH IS
9	VERY ACTIVE IN THE FIELD, PARTICULARLY IN THE AREA
10	OF SOMETHING CALLED INDUCED PLURIPOTENT STEM CELLS,
11	WHICH YOU MAY HAVE HEARD OF. HAPPY TO DISCUSS IF
12	ANYBODY HAS ANY QUESTIONS. BUT WITHOUT GETTING INTO
13	IT, THE JAPANESE REGULATORS WANTED TO DEVELOP A
14	PROCESS THAT ALLOWED FOR A MORE STREAMLINED PROCESS
15	TO GET POTENTIAL THERAPIES TO THE PATIENTS. AND
16	THEY HAVE NOW IMPLEMENTED THAT AND ACTUALLY HAVE
17	TRIALS UNDER WAY WITHIN THAT FRAMEWORK. AND WE HOPE
18	THAT THAT AND SOME OTHERS MAY HELP SERVE AS A MODEL
19	FOR STREAMLINING THE FDA PROCESS.
20	OKAY. WE HAVE ON THE NEXT SLIDE THE
21	FINANCIAL OUTLOOK. THIS IS DOLLARS. THIS ISN'T
22	NUMBERS OF PROJECTS, BUT YOU JUST LOOK AND YOU CAN
23	SEE GOING FORWARD THIS IS THE BREAKDOWN OF HOW WE
24	ANTICIPATE UNDER THE PUSH-PULL-LEVEL PROTOCOL HERE
25	THE DOLLARS THAT WE PLAN TO SPEND IN THE AREAS THAT

1	YOU SEE ENUMERATED IN EDUCATION, DISCOVERY,
2	TRANSLATION, CLINICAL, INFRASTRUCTURE THROUGH THE
3	2020 TIME FRAME WHEN WE EXPECT TO HAVE THE MONEY AT
4	THAT POINT END. YOU CAN SEE IT'S A PRETTY AMBITIOUS
5	SCHEDULE THERE, BUT ONE THAT WE FEEL IS IMMINENTLY
6	DOABLE UNDER OUR PLAN.
7	THE INTENDED OUTCOMES, THIS, AGAIN, FOR
8	MR. LOTT, YOU MIGHT FIND THIS PARTICULARLY
9	INTERESTING. SO AT THE END OF THE DAY, WE THINK
10	THAT AND, OF COURSE, THIS IS ESTIMATES AT THIS
11	POINT, BUT PRETTY GOOD EDUCATED GUESS THAT WE'LL
12	HAVE GENERATED AS MANY AS 50 NEW CLINICAL TRIALS
13	COVERING 20 DIFFERENT TYPES OF DISEASES. FIVE OF
14	THOSE WE THINK WILL BE PEDIATRIC, TEN IN ORPHAN
15	DISEASES. WE HAVE THIS LINE WHERE WE CALL
16	INCREASING THE PROGRESSION EVENT, WHICH SOUNDS LIKE
17	SORT OF SCIENCE SPEAK. WHAT THAT MEANS IS WE TALKED
18	ABOUT SORT OF THE SEAMLESS HANDOFF OF PROJECTS GOING
19	FROM EARLY RESEARCH TO MIDDLE RESEARCH TO CLINICAL
20	TRIALS, AND WE WANT TO BE MORE EFFICIENT ABOUT
21	MOVING THAT ALONG. HERETOFORE THAT HASN'T BEEN AS
22	MUCH THE CASE, AND WE WANT TO GET THAT UP TO WHERE
23	THERE'S A LOT OF PROGRESSION ALONG THAT LINE.
24	THE NEXT, REDUCE PRECLINICAL TIME BY 50
25	PERCENT AND DRIVE IMPLEMENTATION OF A NEW FDA
	26

1	PARADIGM ARE BOTH SORT OF PART AND PARCEL OF THE
2	SAME THING. WE WANT TO TRY TO CONDENSE THE PERIOD
3	THAT IT TAKES TO GET THROUGH THE WHOLE RESEARCH
4	PROCESS AS A MEANS OF GETTING PATIENTS THERAPIES
5	QUICKER.
6	AND THEN LAST, BUT NOT LEAST, ON THE SLIDE
7	WE HOPE TO PARTNER AT LEAST 50 PERCENT OF OUR
8	CURRENTLY UNPARTNERED CLINICAL PROJECTS. WE HAVE
9	ANOTHER 15 THAT WE HAVE ON THE SHEET YOU SEE THERE
10	THAT CURRENTLY ARE ALREADY PARTNERED UP WITH
11	INDUSTRY, AND WE WANT THAT TREND TO CONTINUE AND WE
12	BELIEVE IT WILL. AND THAT IS OUR GOAL THERE.
13	SO THAT CONCLUDES MY REMARKS. AND I'M
14	HAPPY TO ENTERTAIN ANY QUESTIONS THAT YOU MIGHT HAVE
15	ON ANY ASPECT OF OUR PROGRAM.
16	CHAIRWOMAN YEE: THANK YOU VERY MUCH,
17	DR. THOMAS. QUESTIONS OR COMMENTS, MEMBERS? MR.
18	LOTT, PLEASE.
19	MEMBER LOTT: THANK YOU, MADAM CHAIR. I
20	WANT TO CRY. I'M GOING TO SIT HERE AND ACTUALLY
21	CRY. YOU GUYS HAVE DONE A FANTASTIC JOB IN
22	TRANSLATING THIS TO SOMETHING THAT MAKES SENSE FOR
23	AVERAGE PEOPLE. AND YOU MAKE A REALLY GOOD BUSINESS
24	CASE. SOMETHING THAT MOVES AND NOT HAVING
25	COMPLETELY DONE. SO WHAT HAPPENED BETWEEN LAST YEAR
	27

1	AND THIS YEAR? THE NEW PRESIDENT, IS HE
2	RESPONSIBLE?
3	CHAIRMAN THOMAS: I THINK OUR NEW
4	PRESIDENT HAS ADDED HE'S A BUSINESS PERSON.
5	MEMBER LOTT: OH, THANK GOD. I LOVE YOU
6	SCIENTISTS, BUT YOU KNOW.
7	CHAIRMAN THOMAS: THAT ISN'T TO SAY OUR
8	PREDECESSOR WAS NOT THE RIGHT PERSON FOR THAT PERIOD
9	OF CIRM'S LIFE. WHILE DR. TROUNSON WAS PRESIDENT,
10	IT WAS A PERIOD OF EMPHASIS ON ACADEMIC RESEARCH AND
11	MOVING UP THROUGH THAT CONTINUUM I DISCUSSED. BUT
12	IT WAS OUR SENSE THAT, GIVEN WHERE WE ARE NOW AND
13	THAT WE HAVE SO MANY PROJECTS HITTING THE CLINICAL
14	TRIAL PHASE, WE NEEDED A BUSINESS PERSON BECAUSE
15	THAT'S THE BUSINESS END OF THE DEAL. HE BROUGHT TO
16	THE PROCESS ALL THAT COMES WITH THE DISCIPLINE OF
17	BUSINESS. AND HE HAS A DIFFERENT SORT OF OUTLOOK
18	AND I THINK HAS DONE A TERRIFIC JOB OF PUTTING THAT
19	DISCIPLINE AND THAT PERSPECTIVE IN PLACE IN A WAY
20	THAT IMPROVES UPON WHAT WE ALREADY HAD WHICH WE
21	THOUGHT WAS GREAT, BUT NOW IS EVEN BETTER, AND DOES
22	SO IN A WAY THAT HAS ALL THE URGENCY AND ATTENTION
23	TO PATIENTS' NEEDS THAT YOU HAVE TO CONTINUE OUR
24	MISSION.
25	MEMBER LOTT: ALL KIDDING ASIDE. THANK
	38
	, <u>J</u>

1	YOU.
2	CHAIRWOMAN YEE: THANK YOU, MR. LOTT.
3	CHAIRMAN THOMAS: I APPRECIATE THAT.
4	CHAIRWOMAN YEE: DRS. QUICK OR SEDANA, ANY
5	COMMENTS ON YOUR END?
6	MEMBER QUICK: YEAH. THIS IS MICHAEL
7	QUICK. ONE QUESTION. I WAS VERY IMPRESSED BY YOUR
8	MENTION ON THE INFRASTRUCTURE SLIDE OF THE \$850
9	MILLION OF LEVERAGING THAT YOU MANAGED TO DO. DO
10	YOU HAVE A SENSE OF THAT KIND OF LEVERAGING FOR
11	OTHER ASPECTS? SO, FOR EXAMPLE, WHAT I'M THINKING
12	OF IS HOW MUCH FUNDING HAVE YOUR AWARDEES GOTTEN
13	FROM OTHER AGENCIES BECAUSE OF THE CIRM MONEY THAT
14	THEY HAD TO SEED PROJECTS AND THINGS THAT WE WERE
15	GOING AFTER? HAVE YOU HAD ANY ABILITY TO QUANTIFY
16	THE IMPACT OF LEVERAGING SORT OF GRANT DOLLARS TO
17	THE STATE OF CALIFORNIA BECAUSE OF CIRM'S FUNDING TO
18	INVESTIGATORS?
19	CHAIRMAN THOMAS: I THINK THE LEVERAGING
20	IS A BIG WORD FOR US. IT'S ONE THAT WE ARE
21	CONSTANTLY PAYING ATTENTION TO. AND I THINK THAT,
22	WITHOUT QUESTION, THE FACT THAT CIRM HAS BEEN ABLE
23	TO PROVIDE THE FUNDING THAT IT HAS HAS GREATLY AIDED
24	THE INVESTIGATORS IN THEIR APPLICATIONS FOR NIH
25	FUNDING, FOR NSF FUNDING, FOR FUNDING FROM
	39

1	PHILANTHROPISTS, AND IT IS I THINK IF YOU GO OUT
2	AND YOU TALK TO FOLKS THAT WE HAVE FUNDED ABOUT WHAT
3	WE, THROUGH THE TAXPAYERS' VISION, HAVE BEEN ABLE TO
4	IMPLEMENT, HOW THAT HAS IMPACTED WHAT THEY'RE ABLE
5	TO DO IN THE LEVERAGING THEY HAVE BEEN ABLE TO
6	ACCOMPLISH, YOU WILL HEAR ACROSS THE BOARD THAT
7	WE'VE HAD A HUGELY DRAMATIC IMPACT IN THAT WAY.
8	THAT'S A VERY INSIGHTFUL QUESTION BECAUSE
9	YOU DON'T WANT TO BE OUT THERE AS THE ONLY PERSON
10	STANDING. YOU WANT TO BE ABLE TO JUMP START EVEN
11	MORE FUNDING. I CAN'T GIVE YOU A DOLLAR AMOUNT, BUT
12	I CAN GIVE YOU ONE ANECDOTAL COMMENT AFTER ANOTHER
13	ABOUT HOW IMPORTANT CIRM FUNDING HAS BEEN FOR
14	EXACTLY THAT REASON.
15	MEMBER QUICK: IT'S CERTAINLY DIFFICULT TO
16	QUANTIFY, BUT IT WOULD BE A POWERFUL ARGUMENT TO BE
17	MADE FOR FUTURE DISCUSSION WITH THE CALIFORNIA
18	PUBLIC ABOUT FUTURE FUNDING, FOR EXAMPLE, IF ONE
19	COULD FIND A WAY TO NOT ONLY QUANTIFY THAT, BUT I'M
20	SURE YOU'RE KEEPING RECORDS ON HOW MANY OF THESE
21	SORT OF EARLY TRAINING AWARDS ARE RESULTING IN THESE
22	FOLKS STAYING IN SCIENCE AND GETTING GRANTS, ETC.
23	SO I JUST ENCOURAGE YOU TO THINK ABOUT, AS I KNOW
24	YOU ALREADY ARE, THINKING ABOUT HOW BEST TO PRESENT
25	THAT AS A TRUE SUCCESS.

1	CHAIRMAN THOMAS: THANK YOU. THOSE ARE
2	BOTH EXCELLENT SUGGESTIONS. WHEN WE REPORT BACK TO
3	YOU NEXT TIME, WE'LL BE SURE TO HAVE THAT AS A PART
4	OF THE PRESENTATION.
5	ON THE LATTER POINT, WE DO TRACK WHERE OUR
6	VARIOUS EDUCATIONAL AWARDEES GO. IN FACT, THERE'S
7	IN YOUR MATERIALS ONE STORY WHICH IS JUST ONE OF
8	MANY OF ONE OF OUR BRIDGES STUDENTS WHO PARLAYED
9	THAT OPPORTUNITY INTO ACCEPTANCE INTO THE PH.D.
10	PROGRAM AT UCSF AND PLANS TO DO GREAT THINGS IN THE
11	AREA GOING FORWARD. BUT WE WILL MAKE SURE THAT WE
12	HAVE A MORE DETAILED DISCUSSION OF THAT AT OUR NEXT
13	MEETING NEXT YEAR. THANK YOU FOR THAT SUGGESTION.
14	DR. SADANA: THIS KIND OF DOVETAILS INTO
15	WHAT DR. QUICK HAS MENTIONED. AND HOW DO YOU
16	QUANTIFY THE CIRM INTELLECTUAL PROPERTY WHICH IS AS
17	A RESULT OF THIS RESEARCH? HOW DOES THAT GET
18	DISTRIBUTED AND WHO GETS IT? THERE ARE MULTIPLE
19	FUNDINGS INVOLVED IN THE SAME RESEARCH BECAUSE
20	YOU'RE TALKING ABOUT CALIFORNIA PUBLIC MONEY HERE.
21	THAT'S MY QUESTION.
22	CHAIRMAN THOMAS: OKAY. THANK YOU. I'M
23	GOING TO TURN THAT QUESTION TO THE LEGAL ARENA,
24	WHICH I'D BE HAPPY TO GIVE A SHOT AT, BUT YOU'D BE
25	IN MUCH BETTER HANDS WITH OUR GENERAL COUNSEL, MR.
	41

1	HARRISON.
2	MR. HARRISON: GOOD MORNING. THIS IS
3	JAMES HARRISON. SO CIRM DOES HAVE INTELLECTUAL
4	PROPERTY REQUIREMENTS THAT APPLY TO ALL AWARDS.
5	CIRM ITSELF DOES NOT OWN THE IP. THE INVESTIGATORS
6	AND INSTITUTIONS CONTROL THEIR OWN IP, BUT CIRM
7	ENSURES THAT THE STATE OF CALIFORNIA DOES HAVE THE
8	OPPORTUNITY TO BENEFIT FROM THE RESEARCH THE
9	TAXPAYERS HAVE GENEROUSLY FUNDED IN TWO WAYS. ONE,
10	CIRM IMPOSES REQUIREMENTS ON NONPROFIT GRANTEES TO
11	SHARE A PORTION OF THE LICENSE REVENUES THAT THEY
12	RECEIVE WHEN THEY LICENSE A CIRM-FUNDED INVENTION OR
13	TECHNOLOGY, WHICH INCLUDES DATA DEVELOPED IN A
14	CLINICAL TRIAL. SO IF CIRM HAS FUNDED MORE THAN 50
15	PERCENT OF THE PROJECT COSTS, THEN CIRM THE STATE
16	GENERAL FUND, I SHOULD SAY, IS ENTITLED TO 25
17	PERCENT OF THE AWARDEE'S LICENSE REVENUES. IF CIRM
18	HAS FUNDED LESS THAN 15 PERCENT OF THE PROJECT
19	COSTS, THEN THE STATE GENERAL FUND IS ENTITLED IF
20	CIRM HAS FUNDED LESS THAN 50 PERCENT OF THE PROJECT
21	COSTS, THEN THE STATE GENERAL FUND IS ENTITLED TO 15
22	PERCENT OF THE AWARDEE'S LICENSE REVENUES.
23	FOR AN AWARD TO A FOR-PROFIT ENTITY THAT
24	COMMERCIALIZES THE CIRM-FUNDED TECHNOLOGY OR
25	INVENTION, THE STATE GENERAL FUND IS ENTITLED TO A

1	ROYALTY SHARE THAT'S EQUAL TO .1 PERCENT PER ONE
2	MILLION OF CIRM FUNDING. SO FOR A \$10 MILLION
3	AWARD, THE STATE GENERAL FUND WOULD BE ENTITLED TO A
4	ROYALTY OF 1 PERCENT ON ALL COMMERCIAL SALES. AND
5	THAT'S UP TO NINE TIMES THE AMOUNT OF THE AWARD.
6	CHAIRWOMAN YEE: THANK YOU, MR. HARRISON.
7	ANY OTHER QUESTIONS FROM LOS ANGELES? GREAT.
8	DR. THOMAS, I JUST WANT TO THANK YOU FOR
9	THIS PRESENTATION. SOMETHING THAT STRUCK ME AS I
10	WAS LOOKING AT THE SLIDES ON THE FINANCIAL OUTLOOK,
11	AND WHAT I REALLY LIKE ABOUT THE STRATEGIC PLAN AND
12	CERTAINLY THE THEMES OF THE ACTIONS, WHILE IT'S
13	AMBITIOUS, IT'S ALSO ASPIRATIONAL, BUT VERY, VERY
14	ACHIEVABLE. AND SO I THINK IT'S REALLY BASED IN
15	CERTAINLY THE REAL-TIME EXPERIENCE THAT IS HAPPENING
16	TODAY.
17	MY QUESTION, PERHAPS IT'S AN OBSERVATION.
18	AS WE LOOK AT THE FINANCIAL OUTLOOK GOING FORWARD,
19	I'M GOING TO HAVE THE PUBLIC'S HAT ON MOST OF THE
20	TIME AS I SERVE ON THIS COMMITTEE. I THINK IT'S
21	HELPFUL TO JUST ACKNOWLEDGE WHAT'S HAPPENED IN THE
22	PAST RELATIVE TO HOW WE GOT HERE. I DON'T KNOW THAT
23	IT WAS NECESSARILY A LACK OF VISION, BUT CERTAINLY
24	WHEN YOU LOOK AT THE WHOLE FIELD OF STEM CELL
25	RESEARCH AND HOW IT'S EVOLVED, IT GOT OFF TO A
	42

1	PRETTY SLOW START FOR A WHOLE HOST OF REASONS. AND
2	SO I'D LIKE TO KIND OF PUT CIRM'S EXPERIENCE WITHIN
3	THE BROADER CONTEXT OF THE EVOLUTION OF STEM CELL
4	RESEARCH ON A BROADER SCALE, WHETHER IT'S NATIONALLY
5	OR INTERNATIONALLY. CERTAINLY CIRM HAS BEEN A
6	LEADER IN TERMS OF HOW THIS WHOLE FIELD HAS EVOLVED.
7	I THINK THERE'S A STORY TO TELL THERE AND I THINK
8	REALLY PUT THIS INTO CONTEXT FOR THE PUBLIC. SO I
9	HOPE THAT THAT CAN BE DONE.
10	CHAIRMAN THOMAS: THANK YOU. AND I THINK
11	THE FIELD WAS STALLED IN 2004.
12	CHAIRWOMAN YEE: EXACTLY.
13	CHAIRMAN THOMAS: AND THAT ISN'T TO PUT A
14	VALUE JUDGMENT ON PRESIDENT BUSH'S VIEW AT THAT
15	POINT, BUT IT'S JUST A STATEMENT OF FACT. AND CIRM
16	CAME ABOUT IN RESPONSE TO THAT STALLED STATE AND
17	INSTANTANEOUSLY I SHOULD SAY ONCE WE GOT THROUGH
18	THE LITIGATION, AFTER THAT HAD A GIGANTIC EFFECT IN
19	JUMP STARTING THE FIELD. REMEMBER THE FIELD DIDN'T
20	START REALLY TILL 1998 WITH THE ISOLATION OF HUMAN
21	EMBRYONIC STEM CELLS AT THE UNIVERSITY OF WISCONSIN.
22	SO IT'S A BRAND NEW FIELD. FIELDS TAKE TIME TO RAMP
23	UP. THERE ARE LOTS OF ASPECTS TO IT, AND SCIENCE
24	DOES TAKE TIME. AND WHAT WE ARE ABOUT IS DRAMATIC
25	IN ALL THE FIELDS THAT WE ARE FUNDING HERE. SO MOST

1	OF WHAT WE DO IS ON THE ORDER OF THE STORY OF THE
2	POLIO VACCINE. WE'RE LOOKING FOR DRAMATIC CHANGES
3	AND HOPEFULLY CURES, AND THAT IS A PROCESS THAT DOES
4	TAKE TIME; BUT STARTING IN 2007, WHEN WE WERE
5	ACTUALLY ABLE TO BEGIN FUNDING, WE'VE MADE WHAT WE
6	THINK IS BOTH DRAMATIC PROGRESS AND A VERY LARGE
7	CONTRIBUTION TO THE FIELD.
8	CHAIRWOMAN YEE: ABSOLUTELY.
9	CHAIRMAN THOMAS: WE WERE EVERY YEAR
10	THERE'S THIS MEETING CALLED THE INTERNATIONAL STEM
11	CELL RESEARCHERS ANNUAL MEETING THAT TAKES PLACE ALL
12	OVER THE WORLD. THIS TIME IT HAPPENED TO BE IN
13	STOCKHOLM. I WAS THERE THIS YEAR. AS WE KNOW, I'M
14	THERE EVERY YEAR WHEREVER THE MEETING IS. CIRM IS
15	ALWAYS HELD UP AS LITERALLY THE ENVY OF THE RESEARCH
16	WORLD. NO PLACE HAS ANYTHING LIKE THIS. NO PLACE
17	HAS THE PROGRAM IN PLACE, NO PLACE HAS THE FUNDING.
18	IT'S A GREAT LUXURY AND IT'S THANKS TO THE VOTERS OF
19	CALIFORNIA WHO TOOK A RISK ON SOMETHING THAT WAS
20	VERY CUTTING-EDGE, NEVER DONE BEFORE, A WHOLE NEW
21	WAY OF FUNDING RESEARCH. AND SO WE CONTINUE TO BE A
22	WORK IN PROGRESS, BUT A LOT OF NEAT STUFF GOING ON.
23	CHAIRWOMAN YEE: ABSOLUTELY. AND I SHARE
24	MR. LOTT'S SENTIMENT. THIS IS VERY EXCITING. AND
25	THE ACCELERATION, CERTAINLY THE MISSION, AND THE

1	GOAL OF THE INITIATIVE ACCELERATING THE DEVELOPMENT
2	OF STEM CELL THERAPIES, I THINK, HAS DEFINITELY BEEN
3	THAT.
4	AND I GUESS MY QUESTION IS ALSO AS WE LOOK
5	AT ESTABLISHING MILESTONES GOING FORWARD, WHAT WOULD
6	THOSE MILESTONES LOOK LIKE? I THINK OBVIOUSLY FOR
7	THE PUBLIC THEY'RE LOOKING AT THE AVAILABILITY OF
8	MARKETABLE THERAPIES; BUT AS WE HAVE SEEN SINCE THE
9	INCEPTION OF THIS FIELD, CERTAINLY 1997 WAS A
10	MILESTONE YEAR, 2007 WAS A MILESTONE YEAR, BUT AS WE
11	LOOK AT THE STRATEGIC PLAN PROCESS, IT SAYS YOU'RE
12	LOOKING AT ESTABLISHING MILESTONES. CAN YOU GIVE US
13	A LITTLE BIT MORE FLAVOR ABOUT WHAT THOSE LOOK LIKE?
14	CHAIRMAN THOMAS: WELL, I THINK AS WE
15	HAPPEN TO BE ON THIS FINANCIAL OUTLOOK SLIDE, THIS
16	IS SORT OF THE MILESTONES PAGE. WE'VE SORT OF SET
17	GOALS FOR THE NUMBER OF PROJECTS THAT WILL BE IN
18	DIFFERENT STAGES. WE HOPE THAT OBVIOUSLY AS THE
19	CLINICAL TRIALS PROCEED, THAT A NUMBER OF THOSE
20	CLINICAL TRIALS REACH FRUITION. WE COMMONLY GET
21	ASKED, WHAT DO YOU THINK IS GOING TO PAN OUT? WHAT
22	DO YOU THINK? IT'S SCIENCE. SO IT'S VERY
23	DIFFICULT. THINGS HAVE TO PLAY THEMSELVES OUT, BUT
24	I WILL SAY THAT WE AT CIRM DO FIRMLY BELIEVE THAT
25	SOME OF THE THINGS THAT WE ARE FUNDING WILL
	46

1	ULTIMATELY BEAR FRUIT. AND AGAIN, EVERYTHING WE'RE
2	GOING AFTER IS REALLY BIG GAME. SO THE EXTENT WE'RE
3	SUCCESSFUL IN ANYTHING, IT WILL FUNDAMENTALLY CHANGE
4	THE LANDSCAPE FOR THAT PARTICULAR DISEASE.
5	BUT I WOULD SAY THAT THE BEST ANSWER IN
6	TERMS OF MILESTONES IS REALLY THIS PAGE HERE. IT
7	GIVES YOU A FEEL FOR WHERE WE FEEL WE NEED TO REACH
8	FOR CONTINUED PROGRESS AND SUCCESS.
9	CHAIRWOMAN YEE: THANK YOU. AND LET ME
10	JUST ASK ONE LAST QUESTION. I WAS ALSO VERY STRUCK
11	BY THE OVERVIEW ABOUT THE INFRASTRUCTURE PROGRAM.
12	AND ONE OF THE THINGS I HOPE WE CAN DO AS WE
13	CONTINUE MOVING FORWARD IS TYING BACK CIRM'S SUPPORT
14	TO THE BROADER ECONOMIC BENEFIT FOR THE STATE. I
15	JUST WANT TO GET YOUR SENSE FOR WHAT THE LONG-TERM
16	FUTURE FOR INFRASTRUCTURE IS BEYOND, I GUESS, THE
17	TAXPAYERS' INVESTMENT.
18	CHAIRMAN THOMAS: RIGHT. SO AS WE'VE SEEN
19	IN RECENT YEARS, THERE'S BEEN A DRAMATIC UP-TICK IN
20	BIOTECHNOLOGY, AND I THINK WE'RE SORT OF SITTING ON
21	THE EDGE OF EXPLOSION OF DEVELOPMENT IN THAT FIELD.
22	AND I FIRMLY BELIEVE THAT BIOTECHNOLOGY WILL BE ONE
23	OF THE MAJOR SUCCESS STORIES OF CALIFORNIA SORT OF
24	FOLLOWING ON THE SUCCESSES OF SILICON VALLEY, AND
25	THE CELLULAR THERAPY IN THE REGENERATIVE MEDICINE
	47

1	SPACE WILL BE A PROMINENT COMPONENT OF THAT SUCCESS
2	STORY. SO I THINK WE'RE IN THE MIDDLE OF WHAT IS I
3	REALLY THINK A GOLDEN ERA OF MEDICAL RESEARCH WHERE
4	WE'VE HAD AND WILL CONTINUE TO HAVE INCREASING
5	ADVANCEMENT, AND CALIFORNIA WILL BE PROMINENTLY
6	INVOLVED AND RIGHT IN THE MIDDLE OF ALL THAT. SO
7	IT'S FOR ALL OF US A VERY EXCITING TIME AND HOPE
8	THAT WE'RE CONVEYING THAT LEVEL OF EXCITEMENT TO YOU
9	AS PART OF THIS DISCUSSION.
10	CHAIRWOMAN YEE: THANK YOU VERY MUCH. AND
11	I WOULD BE REMISS IF I DIDN'T ASK THIS QUESTION.
12	THANK YOU FOR THE ONGOING WORK WITH RESPECT TO
13	REGULATORY REFORM AND ENGAGING A BROADER ARRAY OF
14	PARTNERS IN THAT EFFORT. IS THERE ANYTHING THAT THE
15	STATE OF CALIFORNIA CAN DO IN TERMS OF THAT ARENA
16	AND HELPING IN THAT ARENA?
17	CHAIRMAN THOMAS: WELL, THAT'S A MOST
18	INTERESTING QUESTION. WE ARE IN THE PROCESS OF
19	DEVELOPING A STRATEGY IN THAT REGARD. AND I'M
20	CERTAIN THAT THE STATE OF CALIFORNIA ITSELF COULD
21	PLAY A VERY PROMINENT ROLE IN HELPING WITH THESE
22	DISCUSSIONS. SO WE ARE DELIGHTED TO HEAR THAT YOU
23	WOULD LIKE TO JOIN US IN THIS, AND WE WILL, WITHOUT
24	QUESTION, TALK TO YOU ABOUT THAT AND SOLICIT YOUR
25	THOUGHTS AND HAVE YOU AS A MAJOR COMPONENT OF THAT

1	EFFORT.
2	CHAIRWOMAN YEE: THANK YOU, DR. THOMAS.
3	OTHER COMMENTS, MEMBERS? HEARING NONE, THANK YOU
4	VERY MUCH FOR THE PRESENTATION AND REALLY APPRECIATE
5	THE DISCUSSION BY THE COMMITTEE MEMBERS. THANK YOU.
6	CHAIRMAN THOMAS: THANK YOU VERY MUCH,
7	MEMBERS OF THE COMMITTEE. BEFORE I TURN IT OVER TO
8	MY COLLEAGUE, CHILA SILVA-MARTIN, TO TALK ABOUT
9	FINANCIAL MATTERS, I WOULD LIKE, JUST AS I ALWAYS DO
10	IN THIS SORT OF SETTING, TO DIRECT COMMENTS TO MY
11	BROTHER IN LOS ANGELES AND SAY GO DODGERS.
12	CHAIRWOMAN YEE: THANK YOU VERY MUCH.
13	MR. TORRES: BETTY IS A GIANTS FAN.
14	CHAIRWOMAN YEE: THANK YOU. MEMBERS, WHY
15	DON'T WE MOVE ON TO OUR NEXT AGENDA ITEM, NO. 6. WE
16	WILL HAVE OUR NEXT PANEL JOIN US, AND THAT'S CHILA
17	SILVA-MARTIN, PLEASE COME FORWARD. YOU WILL BE
18	MAKING THE PRESENTATION.
19	MS. SILVA-MARTIN: YES, I WILL BE.
20	CHAIRWOMAN YEE: GREAT. THANK YOU. GOOD
21	MORNING. WELCOME.
22	MS. SILVA-MARTIN: THANK YOU. GOOD
23	MORNING. THANK YOU, MADAM CHAIRMAN AND CONTROLLER,
24	AND THANK YOU, COMMITTEE MEMBERS.
25	THIS MORNING I WILL BE REPORTING ON CIRM'S
	40
	49

1	OPERATIONAL FINANCES.
2	CHAIRWOMAN YEE: MEMBERS, WE'RE LOOKING AT
3	TAB 5 AND 6 FOR DISCUSSION.
4	MS. SILVA-MARTIN: SO THIS MORNING THE
5	PRESENTATION WILL COVER THE FINAL RESULTS OF OUR
6	'14-'15 BUDGET AS WELL AS THE MAJOR DRIVERS
7	IMPACTING THOSE RESULTS. THEN I'LL INTRODUCE THE
8	'15-'16 BUDGET THAT'S APPROVED BY BOTH OUR FINANCE
9	SUBCOMMITTEE AND OUR ICOC BOARD. AND THE '15-'16
10	BUDGET PRESENTATION WILL INCLUDE THE GOALS THAT
11	SUPPORT THE BUDGET, THE MAJOR FACTORS DRIVING THE
12	BUDGET, AS WELL AS SOME RISKS THAT MAY IMPACT THE
13	FINAL RESULTS.
14	SO FIRST, LOOKING AT THE '14-'15 FINAL
15	EXPENDITURE RESULTS
16	CHAIRWOMAN YEE: I'M SORRY. LET ME JUST
17	REFERENCE THAT WE ARE ON TAB 6.
18	MS. SILVA-MARTIN: SO I'LL BE PROVIDING A
19	HIGH LEVEL OVERVIEW OF OUR FINAL EXPENDITURES FOR
20	THE '14-'15 FISCAL YEAR AND TALK A LITTLE BIT ABOUT
21	THE FACTORS THAT IMPACT THOSE NUMBERS.
22	SO THIS CHART HERE REPRESENTS AT THE
23	CATEGORICAL LEVEL WHAT WE WERE APPROVED TO SPEND FOR
24	THE '14-'15 FISCAL YEAR IN THE FIRST COLUMN, IN THE
25	SECOND COLUMN WHAT WE ACTUALLY SPENT, AND THEN THE
	F.O.

1	LAST COLUMN REPRESENTING THE VARIANCE OF THE UNDER
2	OR OVERRUN. SO AS YOU CAN SEE FROM THE FIRST
3	COLUMN, WE WERE ALLOCATED A TOTAL OF JUST UNDER
4	\$17.3 MILLION. WE SPENT JUST UNDER \$16 MILLION OR
5	15.8 MILLION, TO BE MORE PRECISE, RESULTING IN AN
6	UNDERRUN OF ABOUT \$1.5 MILLION.
7	SO AS YOU CAN SEE FROM THE CHART, THERE'S
8	A COUPLE OF CATEGORICAL AREAS WHERE WE HAD FAIRLY
9	SIGNIFICANT UNDERRUNS, AND THAT WAS IN EMPLOYEE
10	EXPENSES AND REVIEWS, MEETINGS, AND WORKSHOPS, BUT
11	WE ALSO HAD SOME UNDERRUNS IN EXTERNAL SERVICES AND
12	IN OUR GENERAL EXPENDITURE CATEGORY THAT INCLUDES
13	OUR OFFICE RELOCATION. SO I'D LIKE TO JUST BRIEFLY
14	TALK ABOUT SOME OF THESE UNDERRUNS AND OVERRUNS.
15	SO EMPLOYEE EXPENSES WAS WHERE WE HAD THE
16	LARGEST UNDERRUN. AND THAT'S REALLY A RESULT OF OUR
17	REORGANIZATION. SO AS DR. THOMAS INDICATED, IN MAY
18	OF 2014, DR. MILLS WAS APPOINTED TO OUR
19	ORGANIZATION. AND THE FIRST THING THAT DR. MILLS
20	DID WAS REALLY COME IN AND LOOK AT ALL OF OUR
21	OFFICES, HE LOOKED AT OUR ORGANIZATIONAL STRUCTURE,
22	HE TALKED TO OUR TEAM MEMBERS AND SCIENTISTS AND
23	VARIOUS STAKEHOLDERS. AND WITH THAT INFORMATION, HE
24	THEN MOVED FORWARD TO REORGANIZE OUR OPERATIONS. SO
25	AT THE TIME THAT THIS OCCURRED, WE HAD VARIOUS
	F-1

1	VACANCIES. AND INSTEAD OF FILLING THOSE VACANCIES,
2	BECAUSE WE WERE GOING THROUGH A REORGANIZATION, WE
3	ELECTED TO KEEP THEM OPEN AND, AS A MATTER OF FACT,
4	WE ELIMINATED MANY OF THOSE POSITIONS AND PUT IN
5	PLACE OTHER POSITIONS THAT BETTER SUPPORTED THE
6	REORGANIZATIONAL STRUCTURE. SO THAT WAS REALLY THE
7	REASON FOR THE SIGNIFICANT UNDERRUN IN EMPLOYEE
8	EXPENSES. IT WAS THE SALARY SAVINGS FROM THOSE
9	POSITIONS AS WELL AS THE BENEFITS ASSOCIATED WITH
10	THE POSITIONS.
11	THE OTHER AREA WHERE WE HAD UNDERRUNS WAS
12	IN OUR REVIEWS, MEETINGS, AND WORKSHOPS. AND,
13	AGAIN, REALLY IT WAS ATTRIBUTABLE TO THE
14	REORGANIZATION. SO THE FIRST PROGRAM THAT DR. MILLS
15	REORGANIZED WAS OUR CLINICAL PROGRAMS. AND FOR THE
16	'14-'15 FISCAL YEAR, WE HAD ORIGINALLY PLANNED TO
17	HOLD EIGHT CLINICAL ADVISORY PANEL REVIEWS; BUT,
18	BECAUSE WE WERE GOING THROUGH THE REORGANIZATION, WE
19	ONLY HELD TWO OF THE EIGHT REVIEWS. SIMILARLY, WE
20	HAD SEVERAL GRANT REVIEWS SCHEDULED FOR THE FISCAL
21	YEAR; BUT, BECAUSE OF THE REORGANIZATION, WE
22	ELIMINATED TWO OF THOSE REVIEWS AND WE DID NOT HOLD
23	THEM, SO IT RESULTED IN A PRETTY SIGNIFICANT
24	SAVINGS.
25	THERE WAS A COUPLE OF AREAS WHERE WE DID

1	HAVE OVERRUNS. ONE OF THEM WAS IN EXTERNAL
2	SERVICES, AND IT WAS REALLY ATTRIBUTABLE TO A COUPLE
3	OF AREAS. ONE OF THEM IS OUR RELOCATION. SO AS YOU
4	MAY BE AWARE, CIRM HAS REALLY BENEFITED FROM A
5	WONDERFUL FREE RENT FOR THE FIRST ELEVEN YEARS OF
6	ITS EXISTENCE; BUT UNFORTUNATELY THAT FREE RENT GOES
7	AWAY AT THE END OF THIS MONTH. SO WE SPENT A
8	SIGNIFICANT PORTION OF LAST YEAR LOOKING FOR NEW
9	HEADQUARTERS. WE FOUND NEW HEADQUARTERS AND WE DID
10	INCUR SOME COSTS IN THAT AREA BECAUSE WE HIRED AN
11	ARCHITECT AND SPACE DEVELOPMENT ENGINEERS TO HELP US
12	DEVELOP OUR NEW SPACE.
13	AS A RESULT OF THE REORGANIZATION, WE ALSO
14	HAD TO RELEASE NEW PROGRAM ANNOUNCEMENTS, AND THAT
15	REQUIRED PROGRAMMING IN OUR I.T. SYSTEM. AND SO WE
16	HIRED A ONE-TIME COST FOR I.T. PROGRAMMERS.
17	THE OTHER AREA WHERE WE EXPERIENCED SOME
18	OVERRUN IS IN THE CATEGORY WE CALL EQUIPMENT,
19	SUPPLIES, WHERE WE PUT OUR OFFICE RELOCATION. SO AS
20	PART OF THE OFFICE RELOCATION, WE'VE BEEN IN OUR
21	CURRENT SPACE FOR TEN YEARS. WE HAVE FURNITURE
22	THAT'S TEN YEARS OLD. WE DOWNSIZED OUR SPACE FROM
23	WHAT WE CURRENTLY HAVE BY ALMOST 3,000 SQUARE FEET,
24	SO THE MODULAR FURNITURE AND THE FURNITURE THAT WE
25	CURRENTLY HAVE IN OUR SPACE WILL NOT FIT IN THE NEW

1	LOCATION. THE FURNITURE WAS OLD AND IT'S NOT
2	ERGONOMIC. IT'S EXPENSIVE TO TEAR DOWN MODULAR
3	FURNITURE AND REBUILD IT. SO FOR ALL OF THOSE
4	REASONS, WE DID INCUR A ONE-TIME COST OF ABOUT
5	\$380,000 FOR THOSE COSTS.
6	SO THAT REALLY EXPLAINS THE OVERRUNS AND
7	THE UNDERRUNS IN THE '14-'15 FISCAL YEAR, AND NOW
8	WHAT I'D LIKE TO DO IS MOVE ON TO THE '15-'16
9	BUDGET.
10	AND FIRST, I'D LIKE TO TALK ABOUT THE
11	GOALS THAT THE '15-'16 BUDGET SUPPORT. SO WHAT DO
12	WE PLAN TO DO DURING THE '15-'16 FISCAL YEAR? SO AS
13	I MENTIONED EARLIER, WE IMPLEMENTED A
14	REORGANIZATION. AND ACTUALLY DURING THE LATTER PART
15	OF THE '14-'15 FISCAL YEAR, WE WERE ABLE TO FILL
16	SOME OF THE KEY POSITIONS, BUT WE STILL HAVE SEVERAL
17	OTHER POSITIONS WE FEED TO FILL. SO THAT'S A
18	PRIORITY FOR US DURING THE '15-'16 FISCAL YEAR.
19	WE'VE TALKED A LOT ABOUT OUR CLINICAL
20	PROGRAM AND HOW WE IMPLEMENTED CHANGES TO THAT
21	PROGRAM DURING THE '14-'15 FISCAL YEAR, AND SO WE
22	WANT TO INCREASE CAPACITY AND EFFICIENCY BY
23	REVIEWING 36 NEW PROGRAMS THIS YEAR.
24	DR. THOMAS TALKED ABOUT THE OVERHAUL THAT
25	WE DID ALSO TO OUR DISCOVERY AND TRANSLATIONAL

1	PROGRAMS AS WELL AS OUR EDUCATIONAL PROGRAMS. WE
2	RECEIVED APPROVAL TO MOVE FORWARD WITH THOSE
3	PROGRAMS AT OUR JULY BOARD MEETING; AND SO DURING
4	THE '15-'16 FISCAL YEAR, WE PLAN TO FULLY LAUNCH
5	THOSE PROGRAMS. WE ALSO PLAN TO COMPLETE THE
6	INITIAL PHASE OF OUR ALPHA CLINIC NETWORK BY
7	LAUNCHING THE ACCELERATING CENTER. AND, OF COURSE,
8	SINCE WE MADE OVERHAULS TO ALL OF OUR SCIENTIFIC
9	PROGRAMS, WE ALSO NEED TO OVERHAUL OUR OPERATIONAL
10	ACTIVITIES TO ENSURE THAT IT SUPPORTS OUR MISSION
11	AND MOVES THE PROGRAMS FORWARD. SO WE WILL BE DOING
12	THAT AS WELL DURING THE '15-'16 FISCAL YEAR.
13	AND LAST, BUT NOT LEAST, WE WANT TO
14	COMPLETE THE RELOCATION WITHOUT ANY SERVICE
15	INTERRUPTION.
16	SO NOW LOOKING AT THE '15-'16 BUDGET AT A
17	VERY HIGH LEVEL, WHAT I WANTED TO DO IS POINT OUT A
18	COMPARISON OF THE '15-'16 BUDGET TO WHAT WAS
19	BUDGETED IN '14-'15 AND WHAT WE ACTUALLY SPENT. SO
20	IN THIS CHART IN THE FIRST COLUMN YOU WILL SEE THE
21	'14-'15 BUDGET. I TALKED EARLIER, \$17.3 MILLION.
22	WHAT WE SPENT IS REFLECTED IN THE SECOND COLUMN,
23	JUST UNDER \$16 MILLION. AND THEN OUR BUDGET
24	ALLOCATION FOR THE '15-'16 FISCAL YEAR IS \$18.7
25	MILLION.

1	SO THE BUDGET FOR THE '15-'16 FISCAL YEAR
2	IS \$1.4 MILLION HIGHER THAN WHAT WAS BUDGETED LAST
3	YEAR. MORE IMPORTANTLY, IT'S ALMOST \$3 MILLION MORE
4	THAN WHAT WE ACTUALLY SPENT FOR THE '14-'15 FISCAL
5	YEAR. SO I WANT TO TALK ABOUT WHAT'S REALLY DRIVING
6	THOSE INCREASES.
7	SO THERE REALLY ARE FOUR ATTRIBUTES THAT
8	ARE DRIVING THE CHANGE. THREE OF THEM ARE INCREASES
9	AND ONE OF THEM IS A DECREASE. THE INCREASES ARE IN
10	OUR EMPLOYEE EXPENSES, IN OUR REVIEWS AND
11	FACILITIES, AND THEN WE ARE EXPECTING TO SEE A
12	SIGNIFICANT DECREASE IN EXTERNAL SERVICES.
13	SO LOOKING AT OUR EMPLOYEE EXPENSE FIRST,
14	SO WHY ARE WE SEEING SUCH A SIGNIFICANT INCREASE FOR
15	THE '15-'16 FISCAL YEAR? SO AS I MENTIONED EARLIER,
16	WE HAD VACANT POSITIONS THROUGHOUT THE '14-'15
17	FISCAL YEAR BECAUSE WE WERE UNDERGOING A
18	TRANSFORMATION AND OVERHAUL. AND SO AT THE LATTER
19	PART OF THE '14-'15 FISCAL YEAR, WE FILLED SEVERAL
20	OF THOSE KEY POSITIONS. WE ARE ACTIVELY FILLING THE
21	REMAINDER OF OUR POSITIONS, AND WE REALLY ARE
22	ANTICIPATING BEING AT OR NEAR FULL STAFF FOR THE
23	ENTIRE YEAR, HOPEFULLY ELIMINATING THE SAVINGS THAT
24	WE HAD LAST YEAR.
25	THE OTHER FACTOR THAT'S IMPACTING THE

1	INCREASE IN THIS AREA IS STATE-MANDATED EMPLOYER
2	CONTRIBUTION COST. SO, AS YOU KNOW, AS A STATE
3	AGENCY, WE ARE REQUIRED TO PAY FOR RETIREMENT,
4	HEALTH BENEFITS, AND OVER THE YEARS WE'VE SEEN
5	INCREASES AND WE CONTINUE TO SEE INCREASES BASED ON
6	THE LATEST INFORMATION WE HAVE FROM THE VARIOUS
7	CONTROL AGENCIES, AND SO THAT'S BUILT INTO OUR
8	BUDGET.
9	CHAIRWOMAN YEE: MS. SILVA-MARTIN, COULD I
10	JUST ASK YOU TO APPROACH THE MICROPHONE A LITTLE BIT
11	MORE CLOSELY FOR OUR MEMBERS IN LOS ANGELES. THANK
12	YOU.
13	MS. SILVA-MARTIN: OKAY. SO WE ALSO
14	ANTICIPATE SEEING INCREASED REVIEW ACTIVITY. AS
15	DR. THOMAS POINTED OUT, WHEN WE DID THE OVERHAUL,
16	PREVIOUSLY, FOR EXAMPLE, IN OUR CLINICAL PROGRAMS,
17	IT COULD TAKE UP TO 24 MONTHS BEFORE AN AWARD
18	ACTUALLY BECAME ACTIVE. WITH THE OVERHAUL THAT DR.
19	MILLS IMPLEMENTED, WE ARE NOW LOOKING AT ABOUT A
20	FOUR-MONTH PERIOD. AND SO WE ARE REVIEWING
21	APPLICATIONS ON AN ONGOING BASIS EVERY MONTH.
22	WE ALSO, SIMILARLY, MADE CHANGES IN OUR
23	DISCOVERY AND TRANSLATIONAL PROGRAMS, AND WE
24	ANTICIPATE THAT THEY WILL SEE SIGNIFICANT REVIEW
25	ACTIVITY FOR THOSE AREAS AS WELL. SO WE BELIEVE

1	THAT THAT WILL RESULT IN INCREASED COST TO THE
2	ORGANIZATION, BUT ULTIMATELY IT WILL ALLOW US TO
3	INCREASE ACCELERATE STEM CELL THERAPIES TO
4	PATIENTS WITH UNMET MEDICAL NEEDS, WHICH IS REALLY
5	OUR GOAL.
6	SO A COST THAT WE'RE GOING TO SEE NOW FOR
7	THE FIRST TIME IN OUR EXISTENCE IS RENT. AND I
8	MENTIONED EARLIER WE HAVE ENJOYED A BENEFIT THAT'S
9	REALLY UNHEARD OF, FREE RENT AND OPERATING COST, FOR
10	THE FIRST ELEVEN YEARS OF OUR EXISTENCE. DURING THE
11	LATTER PART OF LAST YEAR, WE DID SPEND A LOT OF
12	EFFORT FINDING A SPACE, HOPEFULLY AT THE SAME LEVEL
13	OF EXPENDITURE THAT WE HAD BEFORE, BUT THAT DID NOT
14	MATERIALIZE. SO WE HAVE LOCATED AN OFFICE. WE WILL
15	BE MOVING TO OAKLAND IN NOVEMBER, AND WE WILL BEGIN
16	INCURRING COSTS DURING THE '15-'16 FISCAL YEAR.
17	SOME OF THE COST IS ONE TIME ASSOCIATED WITH THE
18	MOVE, ABOUT 400,000 OF THAT, AND THE REMAINDER IS
19	GOING TO BE FOR ONGOING RENT EXPENSES.
20	SO THE AREA THAT WE ARE SEEING A REDUCTION
21	IN THE '15-'16 FISCAL YEAR OVER WHAT WAS SPENT FOR
22	'14-'15 IS IN EXTERNAL SERVICES. AND THERE'S A
23	COUPLE OF REASONS. MOST OF IT I TALKED ABOUT
24	BEFORE, AND THAT WAS WE DID HAVE SOME ONE-TIME COSTS
25	ASSOCIATED WITH THE RELOCATION OF OUR OFFICE BY
	50

1	HIRING CONSULTANTS TO ASSIST US WITH OUR DESIGN OF
2	OUR NEW OFFICES, BUT ALSO IN REPROGRAMMING OUR I.T.
3	TO BETTER SUPPORT THE NEW PROGRAM ANNOUNCEMENTS.
4	THE OTHER THING THAT WE ALSO INCURRED IN
5	'14-'15 THAT WILL NOT OCCUR DURING THE '15-'16
6	FISCAL YEAR IS A PERFORMANCE AUDIT THAT MARIA
7	BONNEVILLE WILL TALK ABOUT LATER TODAY. WE INCUR
8	THOSE COSTS EVERY THIRD YEAR. SO LAST YEAR,
9	'14-'15, WAS THE YEAR THAT WE HAD TO DO THE
10	PERFORMANCE AUDIT, AND WE WILL NOT SEE THOSE COSTS
11	FOR ANOTHER TWO YEARS.
12	SO, AS WITH ANYTHING, THERE ARE SOME RISKS
13	ASSOCIATED THAT COULD BE INCURRED, AND SO I WANT TO
14	TALK BRIEFLY ABOUT THINGS THAT WE DON'T HAVE
15	COMPLETE CONTROL OF THAT COULD HAVE AN IMPACT ON THE
16	FINANCIAL RESULTS FOR THE '15-'16 FISCAL YEAR.
17	SO THE FIRST POTENTIAL RISK IS APPLICATION
18	VOLUME. SO, AS YOU KNOW, WE CHANGED THE WAY WE DO
19	THINGS. AND WE ARE NOW REVIEWING APPLICATIONS MORE
20	FREQUENTLY; AND ALTHOUGH WE DO HAVE SOME HISTORY OF
21	OF APPLICATIONS FROM OUR PREVIOUS PROCESSES, WE
22	DON'T HAVE A LOT OF EXPERIENCE WITH OUR CURRENT
23	PROCESS. SO IT'S VERY POSSIBLE THAT WE WILL RECEIVE
24	AN UNUSUALLY HIGH NUMBER OF APPLICATIONS, AND SO THE
25	COSTS ASSOCIATED WITH THE REVIEW MAY RESULT IN A

1	HIGHER EXPENDITURE THAN WHAT WAS BUDGETED.
2	OUR RELOCATION, WE HAVE ENTERED INTO AN
3	AGREEMENT AND WE DO HAVE A LEASE SIGNED, BUT WE
4	STILL HAVE NOT OBTAINED FINAL COSTS ASSOCIATED WITH
5	THE RELOCATION. SO AS I SPEAK, CONSTRUCTION IS
6	GOING ON, SO WE MAY FIND THAT WE HAVE MORE COST THAN
7	WE ANTICIPATED FOR CONSTRUCTION. WE'RE STILL
8	NEGOTIATING FOR SOME OF THE SERVICES SUCH AS OUR
9	MOVERS, AND SO IT'S POSSIBLE THE COSTS THAT WE
10	ANTICIPATED MAY BE HIGHER THAN WHAT WE BUDGETED AND
11	IT COULD HAVE AN IMPACT ON OUR BUDGET.
12	WE TALKED ABOUT THE POSITIONS THAT WE HAVE
13	VACANT. AND WHILE WE'VE BEEN VERY LUCKY FOR THE
14	FIRST PART OF THE FISCAL YEAR IN FILLING POSITIONS,
15	IT'S POSSIBLE THAT WE MAY NOT BE ABLE TO ATTRACT
16	CANDIDATES TO FILL THE POSITIONS OR THAT WE MAY
17	EXPERIENCE HIGHER THAN EXPECTED TURNOVERS. AND IF
18	THAT HAPPENS, WE MAY FIND THAT OUR EMPLOYEE EXPENSES
19	COME IN UNDER BUDGET.
20	AND THEN FINALLY, THE LAST RISK FACTOR IS
21	THE STATE-IMPOSED CONTRIBUTIONS. SO WE HAVE
22	BUDGETED BASED ON THE LATEST INFORMATION THAT WE
23	HAVE FROM THE CONTROL AGENCIES. BUT AS YOU ARE
24	AWARE, SOMETIMES THEY MAKE ADJUSTMENTS FOR THOSE
25	EXPENSES IN THE FALL. AND SO IF THEY INCREASE

1	SIGNIFICANTLY, IT MAY IMPACT OUR BUDGET.
2	UNFORTUNATELY THESE ARE EXPENSES THAT CIRM DOES NOT
3	NEGOTIATE. IT REALLY IS UP TO THE STATE AGENCIES,
4	CONTROL AGENCIES, AND SO WE HAVE TO RELY ON WHAT
5	HAPPENS DURING THOSE PROCESSES. SO OUR BUDGET MAY
6	NEED TO BE FURTHER ADJUSTED IF, IN FACT, WE FIND
7	THAT THE COSTS ARE SIGNIFICANTLY HIGHER THAN WHAT WE
8	BUDGETED.
9	SO THAT REALLY IS A PRESENTATION OF WHERE
10	WE WERE LAST YEAR ON OUR BUDGET, WHERE WE PLAN TO BE
11	THIS YEAR, AND WHAT GOALS WE INTEND TO MEET WITH THE
12	'15-'16 BUDGET. OUR BUDGET, AS I INDICATED EARLIER,
13	WAS APPROVED BY OUR FINANCE SUBCOMMITTEE IN MAY AND
14	THEN IT WENT TO OUR FULL BOARD AT THE END OF MAY AND
15	THEY TOO APPROVED OUR BUDGET. SO THIS CONCLUDES MY
16	PRESENTATION. ARE THERE ANY QUESTIONS?
17	CHAIRWOMAN YEE: THANK YOU,
18	MS. SILVA-MARTIN. MR. LOTT, PLEASE.
19	MEMBER LOTT: AND I APOLOGIZE AHEAD OF
20	TIME. THIS IS PROBABLY AN IN-THE-WEEDS QUESTION,
21	AND IT RELATES TO THE MOSS-ADAMS PERFORMANCE REVIEW,
22	BUT I NEED TO ASK IT HERE BECAUSE IT MAY BE A BUDGET
23	ISSUE.
24	IN FINDING 3 OF THE MOSS-ADAMS REPORT,
25	THEY WERE TALKING ABOUT THE TIMELY REVIEW OF

1	PROGRESS REPORTS. AND THERE WAS TWO REASONS FOR THE
2	PROBLEM. ONE IS BECAUSE IT'S AN ITERATIVE PROCESS
3	AND IT WENT BEYOND THE DEADLINE, BUT IT ALSO SAID IT
4	WAS A RESOURCE PROBLEM. CAN SOMEONE EXPLAIN IF THAT
5	RESOURCE PROBLEM HAS BEEN ADDRESSED? DOES IT NEED
6	TO BE IN THIS BUDGET? IS IT IN THIS BUDGET?
7	CHAIRWOMAN YEE: MR. HARRISON.
8	MR. HARRISON: SO I WILL SPEAK FURTHER
9	ABOUT THE MOSS-ADAMS REPORT IN A MINUTE, BUT TO
10	ANSWER YOUR SPECIFIC QUESTION, THE TWO
11	RECOMMENDATIONS RELATING TO THE PROGRESS REPORTS
12	ADDRESS DISEASE, FIRST, THE TIMELINESS OF THE REVIEW
13	OF PROGRESS REPORTS BY CIRM SCIENCE OFFICERS, AND
14	THE SECOND RECOMMENDATION WENT TO CIRM'S ENFORCEMENT
15	OF DELAYS IN THE FILING OF PROGRESS REPORTS BY
16	AWARDEES. YOUR QUESTION REALLY GOES TO THE
17	RESOURCES CIRM HAS TO TIMELY REVIEW PROGRESS
18	REPORTS.
19	WE BELIEVE THAT IT IS A PRIORITIZATION
20	ISSUE AND THAT OUR EXISTING TEAM WITH, THE NEW
21	RECRUITS THAT WE ARE PLANNING TO BRING ON, IS
22	CAPABLE OF REVIEWING THOSE PROGRESS REPORTS IN A
23	MORE TIMELY MANNER AND THAT THE SYSTEM THAT WE'VE
24	ESTABLISHED THROUGH CIRM 2.0, WHICH INVOLVES MORE
25	CLOSELY MONITORING THE AWARDS AND WORKING MORE
	62

1	CLOSELY WITH THE AWARDEES OVER THE COURSE OF THE
2	PROGRAM, WILL ACTUALLY ENABLE US TO COMPLETE THOSE
3	REVIEWS IN A TIMELY WAY. SO WE THINK THERE'S
4	SUFFICIENT RESOURCES AND THAT IT WILL NOT AFFECT THE
5	BUDGET.
6	MEMBER LOTT: THANK YOU.
7	CHAIRWOMAN YEE: THANK YOU, MR. LOTT.
8	QUESTIONS FROM LOS ANGELES?
9	MEMBER QUICK: YES. JUST A QUESTION ON
10	EMPLOYEE EXPENSES GOING UP A SIGNIFICANT AMOUNT FOR
11	THE '15-'16 BUDGET. AND I REALIZE THAT'S WITH AN
12	EXPECTATION OF FULL STAFFING, BUT COULD I GET A
13	SENSE OF WHAT YOU WEREN'T ABLE TO ACCOMPLISH WITH
14	YOUR '14-'15 LEVEL OF STAFFING THAT REQUIRES YOU TO
15	STAFF UP?
16	MS. SILVA-MARTIN: WELL, I CAN SPEAK TO
17	SOME OF IT, AND THEN I THINK THAT OTHER MEMBERS CAN
18	TOO. AS YOU RECALL, ONE OF THE THINGS THAT I
19	MENTIONED WAS A LOT OF EFFORTS WERE REDIRECTED TO
20	THE REORGANIZATION. SO THERE WERE REVIEWS THAT WE
21	DIDN'T HOLD THAT WE ANTICIPATE THAT WE WILL HOLD
22	THIS YEAR THAT WILL REQUIRE THAT WE HAVE FULL
23	STAFFING FOR THAT.
24	MR. HARRISON: THIS IS JAMES HARRISON. I
25	CAN ALSO ADD BRIEFLY TO THAT. THE REORGANIZATION

1	INCLUDED BREAKING CIRM'S TEAM MEMBERS FOR RESEARCH
2	PURPOSES INTO DIFFERENT GROUPS. SO WE ARE NOW
3	ORGANIZED WITH THE DISCOVERY AND TRANSLATION TEAM AS
4	WELL AS A CLINICAL TEAM THAT IS DIVIDED INTO THREE
5	SUBCOMPONENTS BASED ON THERAPEUTIC TARGETS, SO BLOOD
6	AND CANCER, NEURO, AND ORGANS. AND AS A RESULT OF
7	THAT REORGANIZATION AND THE FACT THAT CIRM IS NOW
8	FUNDING MORE CLINICAL TRIALS AND WE EXPECT TO
9	ACCELERATE THAT PACE, AND GIVEN THE CLOSE MONITORING
10	THAT WE INTEND TO UTILIZE WITH THESE PROGRAMS, WE
11	ARE LOOKING AT HIRING SOME ADDITIONAL SCIENCE
12	OFFICERS TO ASSIST US WITH THAT PROCESS.
13	SO I THINK THAT THE DIFFERENTIAL IS IN
14	PART DUE TO THE FACT THAT WE HAVE REORGANIZED, WE
15	HAVE REFINED THE CIRM GRANT MAKING MACHINE, AND WE
16	ANTICIPATE NEEDING SOME ADDITIONAL HANDS TO HELP US
17	ONCE THAT MACHINE STARTS PRODUCING OUTCOME.
18	MEMBER QUICK: THANK YOU.
19	CHAIRWOMAN YEE: THANK YOU, DR. QUICK.
20	OTHER QUESTIONS?
21	DR. SADANA: YES. JUST A LITTLE BIT.
22	CLARIFY A LITTLE BIT ON THE EXTERNAL SERVICES THAT
23	SEEMS TO BE GOING UP A HALF MILLION DOLLARS.
24	MS. SILVA-MARTIN: SO THEY WERE UP THIS
25	YEAR BY APPROXIMATELY, I BELIEVE, \$560,000, AND THAT
	C.4

1	WAS REALLY ONE-TIME COSTS THAT WILL NOT OCCUR NEXT
2	YEAR. AND THEY REALLY ARE RELATED TO THE
3	RELOCATION. SO WE ARE MOVING TO NEW HEADQUARTERS.
4	THE SPACE HAS TO BE DESIGNED. AND SO TO ASSIST US,
5	BECAUSE WE DO NOT HAVE THE EXPERTISE IN-HOUSE, WE
6	HIRED ONE-TIME ARCHITECT, ONE-TIME COSTS FOR
7	ARCHITECTS AS WELL AS FOR ENGINEERS TO ENSURE THAT
8	THE SPACE WORKED FOR US. AND SO THEY HAVE BEEN
9	INSTRUMENTAL IN MOVING THE PROJECT FORWARD. THEY
10	ALSO ARE MANAGING THE PROJECT IN EVERY ASPECT OF THE
11	CONSTRUCTION.
12	SIMILARLY, WHEN WE DID THE OVERHAUL AND
13	REORGANIZED OUR PROGRAMS, WHEN WE HAVE GRANT AWARDS,
14	WE PUBLICIZE THE OPPORTUNITIES ON OUR WEBSITE. WE
15	CHANGED THE WAY WE'RE DOING THE REVIEWS AND THE
16	GRANTS, AND SO WE HAD TO MAKE CHANGES TO OUR
17	INFRASTRUCTURE, OUR I.T. INFRASTRUCTURE, TO SUPPORT
18	THE NEW PROGRAM ANNOUNCEMENT. SO WE HAD TO, AGAIN,
19	SPEND TIME IN CONSULTING SERVICES FOR A PROGRAMMER
20	TO COME IN AND MAKE THOSE CHANGES TO OUR SYSTEM.
21	AND THEN AGAIN, THE LAST THING THAT'S IN
22	THERE THAT YOU WON'T SEE NEXT YEAR IS THE
23	PERFORMANCE AUDIT THAT WE'RE REQUIRED TO CONDUCT
24	EVERY THREE YEARS. SO THOSE WERE EXPENSED IN
25	'14-'15 FISCAL YEAR AND THEY WILL NOT OCCUR NEXT

1	YEAR I'M SORRY IN THE '15-'16 FISCAL YEAR.
2	CHAIRWOMAN YEE: THANK YOU, DR. SEDANA,
3	DR. QUICK.
4	LET ME JUST ASK YOU, AND I THINK THIS MAY
5	HAVE BEEN ANSWERED IN PART, BUT OBVIOUSLY THE TALENT
6	THAT'S REQUIRED TO FULFILL THE MISSION AND THE
7	GOALS, CAN YOU JUST SPEAK WITH A LITTLE BIT MORE
8	FLAVOR ABOUT THE TYPE OF TALENT THAT HAS BEEN
9	ESPECIALLY CHALLENGING TO RECRUIT AND RETAIN? I WAS
10	STRUCK BY THE SLIDE ABOUT NOT BEING ABLE TO ATTRACT
11	QUALIFIED CANDIDATES TO FILL THE POSITIONS AND THEN
12	ALSO EXPERIENCE IN HIGHER THAN EXPECTED TURNOVER.
13	MS. SILVA-MARTIN: I'M GOING TO TURN IT
14	OVER TO MR. HARRISON AGAIN.
15	MR. HARRISON: SO THAT REALLY IS RISK.
16	CIRM HAS BEEN BLESSED IN ITS ABILITY TO ATTRACT AN
17	INCREDIBLY HIGH CALIBER TEAM, NOTWITHSTANDING THE
18	POTENTIALLY SHORT LIFE SPAN OF THE AGENCY. AND I
19	THINK THAT'S IN PART DUE TO THE FACT THAT CIRM'S
20	MISSION IS REALLY SO UNIQUE, AND EVERY EMPLOYEE WHO
21	DECIDES TO JOIN THE TEAM DECIDES TO JOIN THE TEAM
22	FOR THAT REASON. THEY'RE REALLY ATTRACTED TO THE
23	IDEA THAT THIS AGENCY EXISTS TO ACCELERATE THE
24	DEVELOPMENT OF THERAPIES FOR PATIENTS WITH UNMET
25	MEDICAL NEEDS. SO THAT'S BEEN A HUGE ASSET IN OUR

1	ABILITY TO RECRUIT EMPLOYEES.
2	AS CHILA SAID, WE HAVE GONE THROUGH A
3	REORGANIZATION. AND ANY TIME THAT HAPPENS, THERE IS
4	SOME DISRUPTION AND SOME TURNOVER. SO WE HAVE
5	EXPERIENCED THAT. BUT WE ARE IN THE PROCESS OF
6	RECRUITING FOR NEW POSITIONS, AND, IN FACT, RECENTLY
7	HIRED A VICE PRESIDENT FOR THERAPEUTIC DEVELOPMENTS
8	WHO CAME FROM THE GENENTECH COMPANY AND WAS FORMERLY
9	A PROFESSOR AT STANFORD. SO WE ARE ATTRACTING VERY,
10	VERY HIGH CALIBER PEOPLE, AND WE EXPECT TO CONTINUE
11	TO DO SO, BUT WE RECOGNIZE THAT, GIVEN THE AGENCY'S
12	SHORT LIFE SPAN, IT'S GOING TO CONTINUE TO BE A
13	CHALLENGE FOR US TO BOTH RECRUIT THOSE FOLKS AND TO
14	RETAIN THEM. SO WE ARE WORKING AS PART OF OUR
15	REVAMPING OF THE AGENCY'S INTERNAL POLICIES ON IDEAS
16	TO ENSURE THAT WE CAN RETAIN THE TALENT THAT WE
17	HAVE.
18	CHAIRWOMAN YEE: IT'S A VERY SPECIALIZED
19	TALENT.
20	MR. HARRISON: ABSOLUTELY.
21	CHAIRWOMAN YEE: DR. THOMAS.
22	CHAIRMAN THOMAS: I WOULD JUST, NOT SO
23	MUCH IN ANSWER TO THAT QUESTION, BUT JUST TO AUGMENT
24	THE PREMISE OF YOUR QUESTION, WHICH IS JUST TO SAY,
25	WHICH WE DO EVERY YEAR, THE QUALITY OF THE TEAM THAT

1	CIRM HAS AMASSED IS SO IMPRESSIVE AS REPRESENTED BY
2	MEMBERS HERE TODAY AND OUR MANY SCIENCE OFFICERS AND
3	OTHERS WHO SUPPORT THE EFFORTS. IT IS A REAL
4	PRIVILEGE TO BE ABLE TO FOR ALL OF US BE A PART OF
5	SUCH A TALENTED, SUCH A DEDICATED GROUP, WITH SUCH
6	HIGH LEVEL OF EXPERTISE WHICH, FOR SOMETHING LIKE
7	THIS, YOU REALLY NEED TO HAVE BECAUSE IT IS VERY
8	SPECIALIZED. AND JUST WANTED TO NOT LET THE
9	OPPORTUNITY PASS TO REITERATE THAT POINT BECAUSE WE
10	DO FEEL THAT THE STATE IS IN GREAT HANDS WITH THOSE
11	THAT WORK AT CIRM, AND THE TEAM IS DOING WONDERFUL
12	THINGS TO ADVANCE ITS MISSION.
13	CHAIRWOMAN YEE: ABSOLUTELY. THANK YOU.
14	IS IT FAIR TO SAY, THEN, THAT THE CIRM 2.0
15	INITIATIVE, BECAUSE OF THE EMPHASIS ON INCREASING
16	EFFICIENCIES, HEIGHTENS THE RISK WITH RESPECT TO
17	BRINGING THAT TYPE OF TALENT ON BOARD AND RETAINING
18	THEM? IS THAT OKAY. THANK YOU.
19	OTHER QUESTIONS, MEMBERS? THANK YOU VERY
20	MUCH, MS. SILVA-MARTIN.
21	MEMBERS, WE'LL NOW MOVE ON TO THE
22	MOSS-ADAMS PERFORMANCE AUDIT FINAL REPORT. AND
23	MR. JAMES HARRISON WILL BE PRESENTING ON THIS ITEM.
24	I THINK WE'RE LOOKING AT TAB 7 THROUGH 9 ON THIS; IS
25	THAT CORRECT?

1	MR. HARRISON: I BELIEVE THIS IS THE LAST
2	TAB IN ITEM NO. 6. THIS IS OUR POWERPOINT
3	PRESENTATION WITH RESPECT TO THE MOSS-ADAMS
4	PERFORMANCE REVIEW.
5	CHAIRWOMAN YEE: IT MAY BE IN OUR
6	BINDER MEMBERS, WE'RE ON TAB 7. IT'S THE
7	PRESENTATION DATED OCTOBER 1ST.
8	MR. HARRISON: GOOD MORNING AGAIN. JAMES
9	HARRISON. THANKS FOR GIVING US THE OPPORTUNITY TO
10	TALK WITH YOU THIS MORNING. I HAVE THE UNENVIABLE
11	TASK OF TALKING ABOUT THE REALLY NITTY-GRITTY
12	PERFORMANCE REVIEW. SOMETIMES WE AT CIRM FEEL LIKE
13	WE ARE THE MOST AUDITED AGENCY IN THE HISTORY OF THE
14	STATE OF CALIFORNIA. ALONG WITH THE ANNUAL
15	FINANCIAL AUDIT AND THE REVIEW BY THIS BODY, WE ARE
16	ALSO SUBJECT TO A PERFORMANCE REVIEW ONCE EVERY
17	THREE YEARS. AND IN ALL CANDOR, WE SOMETIMES
18	APPROACH THESE AUDITS WITH A LITTLE FEELING OF DREAD
19	BECAUSE THEY OBVIOUSLY REQUIRE A LOT OF WORK, BUT
20	WE'VE REALLY BENEFITED TREMENDOUSLY FROM THESE
21	REVIEWS BY YOU AS WELL AS BY MOSS-ADAMS. THEY HAVE
22	REALLY HELPED US TO FINE-TUNE OUR PERFORMANCE AND
23	ADDRESS DEFICIENCIES. SO WE FEEL REALLY VERY
24	GRATEFUL THAT WE'VE HAD THE OPPORTUNITY TO LEARN AND
25	IMPROVE FROM THESE EXPERIENCES.

1	SO AS I SAID, CIRM IS REQUIRED TO UNDERGO
2	A PERFORMANCE AUDIT ONCE EVERY THREE YEARS. THE
3	FIRST SUCH PERFORMANCE REVIEW OCCURRED FOR FISCAL
4	YEAR 2010 AND 11, AND MOSS-ADAMS JUST RECENTLY
5	COMPLETED ITS PERFORMANCE REVIEW COVERING FISCAL
6	YEAR 13 AND 14. WE DID HAVE THE BENEFIT, HOWEVER,
7	OF SHARING WITH MOSS-ADAMS SOME OF THE CHANGES THAT
8	WE WERE UNDERTAKING AT THAT TIME INVOLVING CIRM 2.0,
9	AND THEY DID ASSIST US BY PROVIDING ADVICE ABOUT HOW
10	WE COULD IMPROVE THOSE PROCESSES EVEN AS THEY WERE
11	IN DEVELOPMENT.
12	ULTIMATELY MOSS-ADAMS COMMENDED CIRM FOR
13	STREAMLINING ITS GRANTS MANAGEMENT SYSTEM, ITS
14	GRANTS REVIEW PROCESS, AND STRENGTHENING THE
15	ORGANIZATIONAL CULTURE. THEY MADE 12 VERY DETAILED
16	RECOMMENDATIONS, ALL OF WHICH WE'RE IN THE PROCESS
17	OF WORKING ON. AND I'D LIKE TO BRIEFLY TAKE YOU
18	THROUGH THOSE. I WILL TRY NOT TO GET LOST IN THE
19	WEEDS, BUT THEY ARE VERY DETAILED, SO I'M JUST GOING
20	TO TRY TO GIVE YOU A BRIEF OVERVIEW AND TELL YOU
21	WHAT WE'RE PLANNING ON DOING.
22	THE FIRST TWO RECOMMENDATIONS RELATE TO
23	FINANCIAL INTEREST DISCLOSURE BY MEMBERS OF CIRM'S
24	GRANTS WORKING GROUP. AND I NEED TO TAKE A STEP
25	BACK HERE TO MAKE SURE THAT YOU UNDERSTAND THE

1	CONTEXT. CIRM'S GRANT REVIEWERS ARE ALL FROM
2	OUT-OF-STATE, AND THAT WAS BY DESIGN IN ORDER TO
3	AVOID CONFLICTS OF INTEREST. WHAT THAT EFFECTIVELY
4	MEANS IS THAT THEY ARE NOT ENTITLED AND CAN'T APPLY
5	FOR CIRM RESEARCH FUNDS. SO THAT'S THE FIRST
6	IMPORTANT POINT.
7	THE SECOND IMPORTANT POINT IS THAT CIRM
8	HAS DEVELOPED A REALLY SOPHISTICATED GRANTS
9	MANAGEMENT SYSTEM. AND BEFORE A REVIEWER CAN EVEN
10	ACCESS AN APPLICATION, THE REVIEWER FIRST HAS TO
11	COMPLETE A CONFLICT OF INTEREST CHECK. THAT
12	CONFLICT OF INTEREST CHECK INCLUDES THE NAMES OF ALL
13	THE APPLICANTS, THE PI, KEY PERSONNEL, AND
14	SUBCONTRACTORS, AS WELL AS CO-FUNDING PARTNERS.
15	EACH REVIEWER HAS TO COMPLETE THAT LIST AND IDENTIFY
16	WHETHER OR NOT HE OR SHE HAS CONFLICTS BEFORE THE
17	GRANTS MANAGEMENT SYSTEM WILL GIVE THE INDIVIDUAL
18	ACCESS TO THE APPLICATION. SO IT'S A VERY
19	SOPHISTICATED AND ROBUST CONFLICT CHECK AND OCCURS
20	BEFORE EACH AND EVERY REVIEW FOR EACH AND EVERY
21	APPLICATION.
22	IN ADDITION TO THAT, WHEN CIRM WAS FIRST
23	ESTABLISHED, WE INCLUDED A REQUIREMENT IN OUR
24	CONFLICT OF INTEREST POLICY FOR GRANTS WORKING GROUP
25	MEMBERS THAT THEY HAD TO FILE A FINANCIAL DISCLOSURE
	7.4

1	REPORT, MUCH LIKE THE FORM 700 THAT YOU FILE, BUT
2	INSTEAD OF DOING IT ON AN ANNUAL BASIS, THEY HAD TO
3	DO IT BEFORE EACH REVIEW. SO IMAGINE FILING YOUR
4	FORM 700 12 TIMES PER YEAR, SINCE WE NOW REVIEW
5	APPLICATIONS ON A MONTHLY BASIS, RATHER THAN ONCE.
6	IT IS A BIT OF A REDUNDANT REQUIREMENT BECAUSE THE
7	REVIEWERS HAVE JUST COMPLETED A REVIEW OF THE
8	SPECIFIC INTEREST INVOLVED IN AN APPLICATION AND
9	THEN THEY HAVE TO DISCLOSE GENERALLY THEIR FINANCIAL
10	INTERESTS. NONETHELESS, IT IS PART OF OUR POLICY
11	AND IT'S SOMETHING THAT OBVIOUSLY WE NEED TO COMPLY
12	WITH.
13	AND THERE WERE INSTANCES THAT MOSS-ADAMS
14	FOUND IN WHICH SOME OF THE REVIEWERS DID NOT
15	COMPLETE THEIR FINANCIAL INTEREST DISCLOSURE FORM
16	BEFORE REVIEWING AN APPLICATION. TO BE CLEAR,
17	MOSS-ADAMS FOUND THAT THEY HAD DONE THE CONFLICT OF
18	INTEREST CHECK, BUT THERE WAS A LAPSE WITH RESPECT
19	TO THE FILING OF THE DISCLOSURE FORM IN SEVERAL
20	INSTANCES.
21	IN ADDITION, AS ANOTHER STEP, CIRM'S
22	GRANTS MANAGEMENT SYSTEM REVIEWS THE FINANCIAL
23	INTEREST DISCLOSURE FORMS AGAINST THE LIST OF
24	APPLICANTS, INSTITUTIONS, KEY PERSONNEL TO DETERMINE
25	WHETHER THERE ARE ANY INTERESTS THAT A MEMBER MAY

1	HAVE OVERLOOKED. SO IT'S ANOTHER DOUBLE-CHECK.
2	UNFORTUNATELY THE GRANTS MANAGEMENT SYSTEM AT THE
3	TIME DID NOT HAVE A MODULE TO DOCUMENT THAT THAT
4	WORK HAD, IN FACT, BEEN COMPLETED. SO WHAT
5	MOSS-ADAMS RECOMMENDED IS THAT WE IMPROVE THE GRANTS
6	MANAGEMENT SYSTEM TO CAPTURE THIS INFORMATION AND TO
7	DOCUMENT THAT WE HAVE, IN FACT, CONDUCTED A REVIEW.
8	SO NOW A MEMBER OF THE GRANTS WORKING GROUP HAS TO
9	COMPLETE OR INDICATE THAT THERE HAVE BEEN NO CHANGES
10	TO HIS OR HER FINANCIAL DISCLOSURE FORM BEFORE
11	GETTING ACCESS TO APPLICATIONS. SO IT'S A SOMEWHAT
12	FOOLPROOF SYSTEM, AND WE'RE ALSO DEVELOPING A SYSTEM
13	IN ORDER TO DOCUMENT THE CROSS-CHECK THAT OCCURS SO
14	WE CAN VERIFY THAT IT'S BEEN DONE IN ALL CASES.
15	THE NEXT TWO RECOMMENDATIONS GO TO A
16	QUESTION MR. LOTT RAISED EARLIER WITH RESPECT TO
17	PROGRESS REPORTS. THIS WAS ONE OF THE
18	RECOMMENDATIONS THAT MOSS-ADAMS MADE THE LAST TIME.
19	WE HAVE IMPROVED, BUT CONTINUE TO EXPERIENCE SOME
20	DELAYS IN THE REVIEW OF PROGRESS REPORTS. SO WITH
21	THE HIRING OF THE NEW VICE PRESIDENT FOR THERAPEUTIC
22	DEVELOPMENT, WE ARE PRIORITIZING THE REVIEW OF THOSE
23	PROGRESS REPORTS. AND, AGAIN, WE THINK WITH CIRM'S
24	NEW, MORE ACTIVE ROLE IN AWARDS AS THEY PROGRESS,
25	THIS WILL ACTUALLY BE RATHER EASY TO ACCOMPLISH

1	BECAUSE IT'S INTEGRAL TO WHAT WE INTEND TO DO IN
2	ORDER TO STAY ON TOP OF THE AWARDS.
3	IN ADDITION, THERE HAVE BEEN OCCASIONS
4	WHEN AWARDS WERE CLOSED BEFORE A FINAL PROGRESS
5	REPORT HAD BEEN FILED, AND WE'VE MADE IMPROVEMENTS
6	TO THE GRANTS MANAGEMENT SYSTEM TO ENSURE THAT THAT
7	DOESN'T HAPPEN.
8	AND THEN FINALLY, THERE ARE OCCASIONS WHEN
9	GRANTEES FILE THEIR PROGRESS REPORTS LATE. WE ARE
10	DEVELOPING A STANDARD OPERATING PROCEDURE TO ENSURE
11	THAT CIRM'S ENFORCEMENT OF LATE PROGRESS REPORTS IS
12	CONSISTENT. SO IF YOU HAVEN'T COMPLETED YOUR
13	PROGRESS REPORT WITHIN 90 DAYS OF THE DATE IT'S DUE,
14	YOU'RE NOT GOING TO GET ADDITIONAL DISBURSEMENTS OF
15	FUNDS UNDER YOUR AWARD.
16	THE NEXT TWO RECOMMENDATIONS RELATE TO IP.
17	SO WE SPOKE A LITTLE BIT ABOUT OUR IP EARLIER. WHEN
18	AN AWARDEE INVENTS SOMETHING, THEY'RE REQUIRED TO
19	REPORT TO CIRM WITHIN 60 DAYS OF NOTIFYING THEIR
20	INSTITUTION OF THAT INVENTION. AND THEN ON AN
21	ANNUAL BASIS THEY HAVE TO REPORT TO US TO TELL US
22	WHETHER THEY'VE UTILIZED THAT INVENTION. SO, FOR
23	EXAMPLE, WHETHER THEY'VE LICENSED IT. WE HAVE
24	EXPERIENCED SOME DIFFICULTY WITH COMPLIANCE WITH THE
25	FILING OF WHAT WE CALL THE ANNUAL UTILIZATION
	7.4

1	REPORT. AND WE HAVE A REQUIREMENT THAT IT HAS TO BE
2	FILED WITHIN 90 DAYS. SO AS WITH PROGRESS REPORTS,
3	WHAT WE PLAN TO IMPLEMENT IN OUR GRANTS MANAGEMENT
4	SYSTEM IS A CHECK TO ENSURE THAT IF AN ANNUAL
5	UTILIZATION REPORT HAS NOT BEEN FILED WITHIN 90
6	DAYS, THEN WE HAVE THE ABILITY TO TERMINATE FUNDING
7	UNTIL THAT OCCURS.
8	ONE OF THE OTHER THINGS THAT MOSS-ADAMS
9	POINTED OUT IS THAT AS WE INCREASINGLY MOVE INTO THE
10	CLINICAL FIELD, WE NEED TO HAVE A MORE ROBUST SYSTEM
11	TO CAPTURE THE KIND OF ACTIVITIES THAT OCCUR THAT
12	WOULD INDICATE TO US THAT THERE MAY BE SOME REVENUES
13	DUE AND OWING TO THE STATE OF CALIFORNIA. SO WE ASK
14	CURRENTLY OUR AWARDEES TO PROVIDE US WITH
15	INFORMATION ABOUT COMMERCIALIZATION ACTIVITIES.
16	MOSS-ADAMS HAS RECOMMENDED AND WE'VE IMPLEMENTED A
17	NEW FIELD THAT REQUIRES THEM TO ADDRESS VERY
18	SPECIFIC QUESTIONS SO THAT WE HAVE THE ABILITY TO
19	VERY CLOSELY MONITOR WHERE THEY ARE IN THE PROCESS
20	OF COMMERCIALIZING A THERAPY SO THAT WE ASSURE THE
21	STATE OF CALIFORNIA HAS THE ABILITY TO CAPTURE ANY
22	REVENUES THAT ARE DUE AND OWING TO IT.
23	THE NEXT RECOMMENDATION GOES TO METRICS.
24	AS CHILA SILVA-MARTIN POINTED OUT IN HER
25	PRESENTATION, WHEN EACH OF THE DEPARTMENTS WITHIN
	75
	<i>1 3</i>

1	CIRM DEVELOPS ITS BUDGET, IT SETS A SERIES OF GOALS
2	FOR THAT DEPARTMENT. HOWEVER, WE HAVE NOT
3	HISTORICALLY DEVELOPED METRICS TO MAKE SURE THAT WE
4	ARE MEASURING THE ACCOMPLISHMENT OF THOSE GOALS.
5	AND MOSS-ADAMS CORRECTLY POINTED OUT THAT WE NEED TO
6	ENSURE THAT THOSE GOALS ARE ACCOMPANIED BY METRICS
7	SO WE CAN MEASURE THE DEPARTMENT'S SUCCESS IN
8	ACCOMPLISHING THAT.
9	WE ARE ALSO, AS PART OF AN OUTGROWTH OF
10	MOSS-ADAMS REVIEW AND AS PART OF CIRM 2.0, LOOKING
11	AT OUR INTERNAL OPERATIONS IN THE SAME WAY WE LOOKED
12	AT OUR GRANT-MAKING PROCESS AND ASKING WHETHER EACH
13	OF OUR POLICIES, PRACTICES, AND PROCEDURES IS
14	NECESSARY, IS ROBUST, IS EFFICIENT, AND WE'RE REALLY
15	TRYING TO TAKE A FRESH LOOK AT ALL OF THOSE POLICIES
16	AND PROCEDURES AND TO REFINE THEM, IF NECESSARY, TO
17	IMPROVE OUR BUSINESS PRACTICES AND OUR EFFICIENCY.
18	THE NEXT RECOMMENDATION GOES IN PART TO A
19	QUESTION RAISED BY CONTROLLER YEE RELATING TO
20	EMPLOYEE ENGAGEMENT. WE HAVE NOTED THAT ONE OF OUR
21	CHALLENGES IS RETAINING THE VERY TALENTED TEAM WE'VE
22	ASSEMBLED, AND MOSS-ADAMS RECOMMENDED THAT WE
23	CONTINUE TO TRY TO IMPROVE EMPLOYEE ENGAGEMENT. DR.
24	MILLS, OUR NEW PRESIDENT, HAS TAKEN STEPS TO ENSURE
25	THAT HAPPENS. WE NOW HAVE QUARTERLY TEAM MEETINGS

1	WHERE WE REVIEW OUR GOALS IN PROGRESS, WHERE TEAM
2	MEMBERS WHO HAVE EXCELLED RECEIVE A GAME BALL AND A
3	COMMENDATION FROM DR. MILLS, AND WE'VE ALSO ENGAGED
4	THE TEAM IN THE RETHINKING OF CIRM. EVERY CIRM TEAM
5	MEMBER PARTICIPATED IN DISCUSSIONS ABOUT CIRM 2.0
6	AND ABOUT CIRM. SO I THINK THAT HAS BEEN EFFECTIVE
7	IN ENSURING THAT ALL MEMBERS OF THE CIRM TEAM ARE
8	ENGAGED IN THE AGENCY'S MISSION AND ITS OPERATIONS
9	AS WELL.
10	OF COURSE, ONE THING EMPLOYEES CARE ABOUT
11	IS COMPENSATION. CIRM HAS IN THE PAST DELAYED
12	IMPLEMENTATION OF MERIT INCREASES AS A RESULT OF
13	DELAYED PERFORMANCE REVIEWS. MOSS-ADAMS NOTED THAT,
14	AND, IN FACT, WE HAVE REVAMPED OUR PERFORMANCE
15	REVIEW PROCESS. AND FOR THIS YEAR WE COMPLETED AND
16	AWARDED MERIT INCREASES BEFORE JULY 1ST, 2015,
17	BEFORE THE BEGINNING OF THE FIRST DAY OF THE FISCAL
18	YEAR. SO WE DID THAT IN A VERY EFFICIENT AND TIMELY
19	MANNER, AND WE INTEND TO CONTINUE TO DO THAT IN
20	ORDER TO ENSURE THAT OUR TEAM MEMBERS ARE
21	APPROPRIATELY REWARDED AND RECOGNIZED FOR THEIR HARD
22	WORK.
23	THE NEXT RECOMMENDATION GOES TO TRENDS IN
24	WEB APPLICATIONS. AS I SAID, CIRM HAS A VERY
25	SOPHISTICATED GRANTS MANAGEMENT SYSTEM. OUR I.T.
	77

1	TEAM CONTINUES TO MONITOR DEVELOPMENTS IN THE FIELD
2	AND TO LOOK AT WAYS TO IMPROVE THAT SYSTEM, AND WE
3	WILL CONTINUE TO DO THAT.
4	SIMILARLY, WE CONTINUE TO LOOK FOR WAYS TO
5	IMPROVE THE GRANTS MANAGEMENT SYSTEM CAPABILITIES
6	GENERALLY. OUR USERS ARE BOTH CIRM TEAM MEMBERS AS
7	WELL AS OUR APPLICANTS AND AWARDEES, AND WE CONTINUE
8	TO WORK WITH THEM TO LOOK FOR IDEAS FOR IMPROVEMENT,
9	TO REDUCE PAPERWORK, AND TO MAKE THIS SYSTEM MORE
10	EFFICIENT AND EFFECTIVE.
11	AND THEN MOSS-ADAMS FINAL RECOMMENDATION
12	WENT TO THE IMPLEMENTATION OF THE RECOMMENDATIONS
13	THEY MADE IN THEIR LAST PERFORMANCE REVIEW. CIRM
14	HAS COMPLETED THE VAST BULK OF THOSE. SOME OF THEM
15	ARE ONGOING, IMPROVEMENT OF THE GRANTS MANAGEMENT
16	SYSTEM, AS I MENTIONED, ACCELERATING THE REVIEW OF
17	PROGRESS REPORTS. ONE OF THE RECOMMENDATIONS WAS TO
18	STREAMLINE STANDING MEETINGS. I THINK MY COLLEAGUES
19	WILL AGREE THAT WE'VE DONE A GOOD JOB OF NOT ONLY
20	STREAMLINING STANDING MEETINGS, BUT IN SOME CASES
21	ELIMINATING THOSE MEETINGS ALTOGETHER.
22	AND THEN FINALLY, RECRUITMENT AND
23	RETENTION WHICH CONTINUES TO BE A CHALLENGE, A RISK,
24	AND A GOAL FOR US. SO WE CONTINUE TO WORK ON ALL OF
25	THOSE ITEMS.

1	THAT CONCLUDES MY PRESENTATION. I'D BE
2	HAPPY TO ANSWER ANY QUESTIONS YOU HAVE.
3	CHAIRWOMAN YEE: THANK YOU, MR. HARRISON.
4	QUESTIONS, MEMBERS? MR. LOTT.
5	MEMBER LOTT: NOT A QUESTION, BUT A
6	COMMENT. I WOULD COMMEND TO MY COMMITTEE MEMBERS
7	AND ASSOCIATES TO ACTUALLY GO INTO THE MOSS-ADAMS
8	REPORT AND LOOK AT THE DETAIL THAT WAS INCLUDED ON
9	THE IMPROVEMENT OF ORGANIZATIONAL CULTURE. YOU JUST
10	KIND OF GLOSSED OVER IT. I WANT TO GO BACK TO THAT.
11	IT'S REALLY IMPORTANT TO KNOW THE CHANGES.
12	I'M NOT GOING TO READ THEM. YOU CAN READ THEM
13	YOURSELVES. BUT IT WOULD SEEM TO ME THAT, AGAIN,
14	THIS GOES BACK TO A COMMENT EARLIER, BUT IT WOULD
15	SEEM TO ME THAT THIS NEW PRESIDENT, DR. RANDY MILLS,
16	HAS DONE A LOT TO CHANGE A LOT.
17	MR. HARRISON: HE HAS. HE HAS. I'VE BEEN
18	WITH CIRM FROM THE START, SO RANDY IS NOW THE THIRD
19	PRESIDENT WHO'S HAD THE OPPORTUNITY TO LEAD THE
20	AGENCY. EACH BROUGHT THEIR OWN SET OF SKILLS TO THE
21	JOB. AS CHAIRMAN THOMAS SAID, I THINK RANDY WAS THE
22	RIGHT PERSON AT THE RIGHT MOMENT IN TIME. HE HAS
23	REALLY REENERGIZED THE TEAM, REFOCUSED US ON OUR
24	MISSION. AS CHAIRMAN THOMAS SAID, HE NOT ONLY
25	REPEATS THAT MISSION STATEMENT BEFORE OR DURING EACH
	79
	· ·

1	BOARD MEETING, BUT EVERY TIME THE CIRM TEAM MEETS
2	TOGETHER, HE FOCUSES ON THAT MISSION. AND
3	EVERYTHING THE TEAM DOES HAS THAT MISSION IN MIND.
4	SO I THINK THAT HAS HELPED TO COALESCE THE TEAM,
5	ENSURE THAT EVERYONE IS ROWING IN THE SAME
6	DIRECTION, AND IMPROVED MORALE GENERALLY. SO I
7	THINK HE'S BEEN VERY EFFECTIVE IN THAT REGARD.
8	MEMBER LOTT: I KNEW IT HAD TO BE
9	IMPORTANT BECAUSE I'M VERY FAMILIAR WITH THE
10	MOSS-ADAMS ORGANIZATION, AND THEY DON'T GIVE THOSE
11	KIND OF COMMENDATIONS OUT VERY LIGHTLY. SO THIS IS
12	QUITE KUDOS TO YOU ALL.
13	MR. HARRISON: THANK YOU. IT WAS
14	DEFINITELY A VERY CLOSE REVIEW.
15	CHAIRWOMAN YEE: THANK YOU, MR. LOTT.
16	DR. SEDANA AND DR. QUICK, YOU HAVE QUESTIONS,
17	COMMENTS?
18	MEMBER SADANA: NOT REALLY, BUT I WOULD
19	CONGRATULATE THEM VERY MUCH FOR DOING A GREAT JOB.
20	THE ONLY THING IS TO MAINTAIN THE TRANSPARENCY OF
21	THE GRANT ISSUING. I BELIEVE THAT'S ALL I WILL MAKE
22	AT THIS POINT. THANK YOU.
23	CHAIRWOMAN YEE: I HAVE A COUPLE OF
24	QUESTIONS. I THINK YOU MENTIONED, MR. HARRISON, THE
25	FINANCIAL INTEREST DISCLOSURE FORMS. DOES CIRM HAVE

80

1	A FILING REQUIREMENT? DID THEY FILE ANYWHERE?
2	MR. HARRISON: CIRM MAINTAINS COPIES OF
3	THEM. THIS IS ALL DONE ELECTRONICALLY. SO THEY'RE
4	MAINTAINED ON OUR GRANTS MANAGEMENT SYSTEM AND ARE
5	AVAILABLE THERE.
6	CHAIRWOMAN YEE: OKAY. GOT IT. AND THEN
7	THIS WHOLE AREA OF MEASURING PERFORMANCE, I'VE GOT
8	TO THINK THAT, AS WE HAVE MORE IMPROVED SCIENTIFIC
9	PROGRESS REPORTS, THAT THAT'S GOING TO HELP INFORM
10	THAT PROCESS.
11	MR. HARRISON: YES. I NEGLECTED TO
12	MENTION THAT CIRM'S GRANTS MANAGEMENT OFFICER,
13	GABRIEL THOMPSON, HAS BEEN ASSIGNED A NEW TASK BY
14	DR. MILLS, AND THAT IS TO WORK ON DEVELOPING
15	PERFORMANCE METRICS FOR OUR AWARDS, OUR PROGRAMS,
16	AND OUR OPERATIONS. SO THAT IS IN THE PROCESS OF
17	BEING DEVELOPED, AND WE DO THINK WE WILL HAVE A MORE
18	ROBUST WAY TO CAPTURE PROGRESS AS A RESULT.
19	CHAIRWOMAN YEE: THANK YOU. AND THEN I
20	HAVE A FEELING I KNOW THE ANSWER TO THIS, AND I'M
21	LOOKING AT HIM. BUT IN YOUR OPINION DOES CIRM
22	POSSESS THE ADEQUATE LEGAL TOOLS TO ENFORCE THE
23	FINANCIAL DISCLOSURE REPORT REGULATIONS?
24	MR. HARRISON: I BELIEVE WE DO, AND I CAN
25	SAY THAT BECAUSE I'M NOT THE PERSON WHO'S PRIMARILY

1	RESPONSIBLE FOR IT. WE HAVE TWO ATTORNEYS, ONE OF
2	WHOM CAME TO CIRM FROM THE GERON CORPORATION WHERE
3	HE WORKED ON IP ISSUES AND ANOTHER ATTORNEY WHO WAS
4	INSTRUMENTAL IN DRAFTING OUR INTELLECTUAL PROPERTY
5	REGS WHO CONTINUES TO BE INVOLVED IN MONITORING AND
6	ENFORCING THEM. SO I THINK WE HAVE A VERY STRONG
7	AND CAPABLE TEAM, AND WE CONTINUE TO LOOK FOR WAYS
8	TO IMPROVE OUR ABILITY TO MONITOR AND TO ENSURE,
9	MOST IMPORTANTLY, THAT OUR AWARDEES COMPLY WITH THE
10	REPORTING REQUIREMENTS THAT ARE ALREADY ON THE
11	BOOKS.
12	CHAIRWOMAN YEE: ALL RIGHT. GOOD.
13	MEMBER LOTT: CONCERNING YOUR POSITION,
14	WOULD YOU SAY NO?
15	MR. HARRISON: THAT WOULD BE A PROBLEM FOR
16	ME, I BELIEVE.
17	CHAIRMAN THOMAS: CAN I JUST ADD ONE
18	COMMENT TO THAT, WHICH IS A SHOUT OUT TO MR.
19	HARRISON. I'VE BEEN INVOLVED WITH GOVERNMENT
20	AGENCIES AND BOARDS FOR MANY YEARS OF ONE SORT OR
21	ANOTHER. AND I KNOW HE HATES IT WHEN I SAY STUFF
22	LIKE THIS, BUT I'VE NEVER SEEN SOMEBODY WHO IS A
23	COUNSEL TO AN AGENCY WHO DOES A BETTER JOB ALL
24	ACROSS THE BOARD THAN MR. HARRISON. SO KUDOS TO
25	YOU, JAMES.
	82
	1 (1/

1	CHAIRWOMAN YEE: A LONG REPUTATION THAT
2	HAS BEEN RESPECTED. THANK YOU. THANK YOU, MR.
3	HARRISON.
4	MR. HARRISON: THANK YOU VERY MUCH.
5	CHAIRWOMAN YEE: MEMBERS, I JUST WANTED TO
6	POSE ONE QUESTION. I REALLY APPRECIATE ALL THE
7	PRESENTATIONS THIS MORNING. AND I'M NOT SURE WHO TO
8	POSE THIS TO. WE RECEIVED THE FINANCIAL REPORT FROM
9	MS. SILVA-MARTIN I APOLOGIZE FOR NOT PRONOUNCING
10	YOUR NAME PROPERLY BUT JUST IN TERMS OF THE
11	PUBLIC'S ACCESS TO COMPLETE ACCOUNTING OR
12	TRANSPARENCY AROUND THE BOND PROCEEDS, IS THERE A
13	SINGLE PLACE WHERE ALL THE FINANCIAL PIECES ARE
14	AVAILABLE FOR THE PUBLIC? SO WE TALKED ABOUT THE
15	OPERATIONAL BUDGET TODAY, BUT IS THERE A SINGLE
16	PLACE WHERE THEY CAN ALSO SEE THE GRANT AWARDS AND
17	OTHER BOND EXPENDITURES?
18	MS. SILVA-MARTIN: FROM A FINANCIAL
19	PERSPECTIVE, OBVIOUSLY THERE IS INFORMATION IN THE
20	ANNUAL SORRY. CAN'T HEAR ME. I APOLOGIZE. SO
21	THE FINANCIAL AUDIT THAT WE WILL FILE TODAY, AND WE
22	HAVE TO FINALIZE THAT, DOES INCLUDE INFORMATION
23	ABOUT WHAT WE'VE AWARDED THUS FAR, BUT I THINK ALSO
24	OUR WEBSITE. I THINK THAT MR. HARRISON MIGHT BE
25	ABLE TO TALK IN MORE DETAIL, BUT OUR WEBSITE DOES
	0.7

1	CONTAIN INFORMATION ABOUT ALL THE AWARDS THAT WE'VE
2	MADE.
3	CHAIRWOMAN YEE: VERY GOOD.
4	MR. HARRISON: WE HAVE A VERY ROBUST
5	WEBSITE.
6	CHAIRWOMAN YEE: YES, IT IS.
7	MR. HARRISON: IT IDENTIFIES EVERY AWARD
8	THAT CIRM HAS EVER MADE, AND IT IS SEARCHABLE. SO
9	THERE IS BROAD ACCESS TO INFORMATION ABOUT THE
10	PROGRAMS THAT DR. THOMAS DISCUSSED EARLIER.
11	WITH RESPECT TO THE BONDS THEMSELVES,
12	THOSE RECORDS ARE MAINTAINED BY THE STATE STEM CELL
13	RESEARCH AND CURES FINANCE COMMITTEE.
14	CHAIRWOMAN YEE: OKAY. THANK YOU.
15	MEMBERS, WE WILL NOW LOOK AT CONSIDERATION OF A
16	DRAFT AGENDA FOR OUR NEXT MEETING. WE HAVE RECEIVED
17	A LOT OF INFORMATION TODAY, AND I'D LIKE TO
18	ENTERTAIN POTENTIAL TOPICS FOR OUR NEXT MEETING AT
19	THIS POINT. MR. LOTT.
20	MEMBER LOTT: IF I MAY, MADAM CHAIR, I AM
21	CONCERNED A LOT ABOUT THE ISSUE OF THE WINDDOWN OF
22	THE AGENCY AND THE BRAIN DRAIN THAT'S INEVITABLY
23	GOING TO OCCUR. ARE YOU ALL I'D LIKE TO SEE IN
24	THE REPORT FOR NEXT TIME AROUND A PLAN FOR
25	CONTINUING TO MEET THE OBJECTIVES WITH SPECIFIC
	0.4

1	SCENARIOS THAT THE AGENCY WILL DEFINE, GIVE SEVERAL
2	DIFFERENT SCENARIOS OF LOSS OF TALENT AND HOW THEY
3	WOULD PROCEED TO CONTINUE TO MEET THE OBJECTIVES
4	UNDER THAT CIRCUMSTANCE.
5	CHAIRWOMAN YEE: AND I WOULD ADD TO THAT
6	THE LONG-TERM MAINTENANCE OF THE INFRASTRUCTURE.
7	THANK YOU.
8	DRS. QUICK AND SEDANA, ITEMS FOR THE NEXT
9	AGENDA?
10	MEMBER QUICK: NOTHING IMMEDIATELY COMES
11	TO MIND TO ME. I'LL CERTAINLY THINK ABOUT IT.
12	DR. SADANA: NO, MADAM CONTROLLER,
13	NOTHING. THE ONLY THING IS MAYBE THE NEXT MEETING
14	THEY SHOULD COME UP OR AT LEAST PRESENT SOME
15	ACHIEVEMENT FROM DOING THE TRIALS AND WHAT PHASES
16	THEY ARE AND WHERE WE ARE WITH THOSE.
17	CHAIRWOMAN YEE: ABSOLUTELY. THAT WILL
18	BE, I'M SURE, HIGHLIGHTED AT OUR NEXT MEETING. AND
19	THEN OBVIOUSLY CONTINUED WORK ON IMPLEMENTING THE
20	RECOMMENDATIONS IN THE PERFORMANCE AUDIT. VERY
21	WELL. THANK YOU. THANK YOU, MEMBERS.
22	WE HAVE NOW THE PUBLIC COMMENT SECTION OF
23	OUR AGENDA. WE HAVE ONE MEMBER OF THE PUBLIC THAT
24	WISHES TO SPEAK, AND THAT IS MARY BASS. PLEASE COME
25	FORWARD. IF YOU WILL INTRODUCE YOURSELF FOR THE

1	RECORD, AND YOU HAVE THREE MINUTES.
2	MS. BASS: WELL, FIRST OF ALL, THANK YOU,
3	MADAM CHAIRMAN.
4	CHAIRWOMAN YEE: STEP RIGHT UP TO THE
5	MICROPHONE.
6	MS. BASS: SURE. FIRST, THANK YOU, MADAM
7	CHAIRMAN, THANK YOU, MEMBERS OF THE BOARD, CHAIRMAN
8	THOMAS. MY NAME IS MARY BASS. I'M WITH THE
9	AMERICANS FOR CURES FOUNDATION, WHICH IS THE
10	NONPROFIT LEGACY ORGANIZATION BEHIND PROPOSITION 71.
11	I WANTED TO LET YOU KNOW THAT OVER THE
12	COURSE OF THE NEXT YEAR AND CONTINUING AFTERWARDS,
13	WE ARE BEGINNING A STATEWIDE REPORT BACK TO THE
14	PUBLIC TO INFORM THE CALIFORNIA VOTERS ABOUT WHAT
15	MILESTONES OF PROGRESS HAVE RESULTED IN THEIR
16	INITIAL INVESTMENT AND THEIR SUPPORT OF PROPOSITION
17	71.
18	SO, FIRST, I WANT TO COMMEND CIRM ON A
19	TREMENDOUS PRESENTATION AND EMPHASIZE OUR SUPPORT,
20	AND I WOULD ENCOURAGE YOU ALL TO KEEP ABREAST OF OUR
21	UPDATES OVER THE NEXT YEAR BECAUSE WE WILL REALLY BE
22	LEVERAGING, AUGMENTING, AND AMPLIFYING THE
23	TREMENDOUS WORK THAT CIRM IS DOING ON THE SCIENTIFIC
24	FRONT AND REALLY INTENDING THAT COMMUNICATION TO THE
25	PUBLIC.
	0.5

ı	
1	CHAIRWOMAN YEE: VERY WELL.
2	MS. BASS: THANK YOU.
3	CHAIRWOMAN YEE: YES, MR. LOTT.
4	MEMBER LOTT: HOW DO WE ACCESS YOUR
5	INFORMATION?
6	MS. BASS: SO OUR WEBSITE IS AT
7	WWW.AMERICANSFORCURES.ORG. WE ALSO HAVE A
8	SIGNIFICANT SOCIAL MEDIA PRESENCE VIA FACEBOOK AND
9	TWITTER. SO I WILL ENCOURAGE YOU TO KEEP UPDATED
10	WITH THAT, AND I CAN PASS ALONG THAT INFORMATION TO
11	ANY INTERESTED PARTIES AFTERWARD AND FOLLOWING UP.
12	CHAIRWOMAN YEE: YOU'LL LEAVE YOUR CONTACT
13	INFORMATION WITH US?
14	MS. BASS: YES.
15	CHAIRWOMAN YEE: WE'LL CIRCULATE THAT TO
16	THE MEMBERS. THANK YOU VERY MUCH.
17	MS. BASS: THANK YOU.
18	CHAIRWOMAN YEE: THANK YOU. MEMBERS, ANY
19	LAST COMMENTS BEFORE WE ADJOURN?
20	DR. SADANA: I DON'T THINK SO.
21	MEMBER QUICK: NOT FOR ME. THANK YOU.
22	CHAIRWOMAN YEE: THANK YOU VERY MUCH FOR
23	YOUR PARTICIPATION AND SERVICE ON THE COMMITTEE.
24	WITH THAT, MEMBERS, WE ARE ADJOURNED. THANK YOU
25	VERY MUCH.
	a-
	87

```
1
                 (THE MEETING WAS THEN CONCLUDED AT 11:10
 2
      A.M.)
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
                                  88
```

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE CITIZENS FINANCIAL ACCOUNTABILITY OVERSIGHT COMMITTEE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

EMERYVILLE CITY COUNCIL CHAMBERS
1333 PARK AVENUE
EMERYVILLE, CALIFORNIA
ON
OCTOBER 1, 2015

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTERS' REPORTING SERVICE 160 S. OLD SPRINGS ROAD SUITE 270 ANAHEIM, CALIFORNIA (714) 444-4100